{ "version": "2.2", "instance": { "abvx-20250331.htm": { "nsprefix": "abvx", "nsuri": "http://www.abivax.com/20250331", "dts": { "inline": { "local": [ "abvx-20250331.htm" ] }, "schema": { "local": [ "abvx-20250331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2024-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd", "https://xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd" ] }, "calculationLink": { "local": [ "abvx-20250331_cal.xml" ] }, "definitionLink": { "local": [ "abvx-20250331_def.xml" ], "remote": [ "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/dimensions/dim_full_ifrs_2024-03-27_role-995000.xml" ] }, "labelLink": { "local": [ "abvx-20250331_lab.xml" ] }, "presentationLink": { "local": [ "abvx-20250331_pre.xml" ] } }, "keyStandard": 208, "keyCustom": 123, "axisStandard": 29, "axisCustom": 6, "memberStandard": 42, "memberCustom": 94, "hidden": { "total": 7, "http://xbrl.sec.gov/dei/2024": 6, "http://www.abivax.com/20250331": 1 }, "contextCount": 629, "entityCount": 1, "segmentCount": 148, "elementCount": 631, "unitCount": 10, "baseTaxonomies": { "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full": 1081, "http://xbrl.sec.gov/dei/2024": 13 }, "report": { "R1": { "role": "http://www.abivax.com/role/Coverpage", "longName": "0000001 - Document - Cover page", "shortName": "Cover page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "longName": "9952151 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:Goodwill", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:OtherNoncurrentNonfinancialAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "unique": true } }, "R3": { "role": "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFLOSS", "longName": "9952152 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF LOSS", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF LOSS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:OtherIncome", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:RevenueAndOperatingIncome", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "unique": true } }, "R4": { "role": "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "longName": "9952153 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProfitLoss", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "unique": true } }, "R5": { "role": "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "longName": "9952154 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS\u2019 EQUITY", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS\u2019 EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-5", "name": "ifrs-full:NumberOfSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "ifrs-full:Equity", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "unique": true } }, "R6": { "role": "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "9952155 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProfitLoss", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "unique": true } }, "R7": { "role": "http://www.abivax.com/role/TheGroup", "longName": "9952156 - Disclosure - The Group", "shortName": "The Group", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.abivax.com/role/Basisofpreparation", "longName": "9952157 - Disclosure - Basis of preparation", "shortName": "Basis of preparation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequentevents", "longName": "9952158 - Disclosure - Significant events for the year ended December 31, 2024 and the three months ended March 31, 2025 and subsequent events", "shortName": "Significant events for the year ended December 31, 2024 and the three months ended March 31, 2025 and subsequent events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "abvx:DisclosureOfSignificantEventsForThePeriodReportedAndEventsAfterReportingPeriodTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "abvx:DisclosureOfSignificantEventsForThePeriodReportedAndEventsAfterReportingPeriodTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.abivax.com/role/Accountingprinciples", "longName": "9952159 - Disclosure - Accounting principles", "shortName": "Accounting principles", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.abivax.com/role/Segmentinformation", "longName": "9952160 - Disclosure - Segment information", "shortName": "Segment information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.abivax.com/role/Goodwillandimpairmenttest", "longName": "9952161 - Disclosure - Goodwill and impairment test", "shortName": "Goodwill and impairment test", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfGoodwillExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfGoodwillExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.abivax.com/role/Intangibleassets", "longName": "9952162 - Disclosure - Intangible assets", "shortName": "Intangible assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.abivax.com/role/Propertyplantandequipment", "longName": "9952163 - Disclosure - Property, plant and equipment", "shortName": "Property, plant and equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.abivax.com/role/Otherfinancialassets", "longName": "9952164 - Disclosure - Other financial assets", "shortName": "Other financial assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfOtherAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfOtherAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.abivax.com/role/Otherreceivablesandotherassets", "longName": "9952165 - Disclosure - Other receivables and other assets", "shortName": "Other receivables and other assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.abivax.com/role/Cashandcashequivalents", "longName": "9952166 - Disclosure - Cash and cash equivalents", "shortName": "Cash and cash equivalents", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.abivax.com/role/Financialassetsandliabilities", "longName": "9952167 - Disclosure - Financial assets and liabilities", "shortName": "Financial assets and liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.abivax.com/role/Shareholdersequity", "longName": "9952168 - Disclosure - Shareholders\u2019 equity", "shortName": "Shareholders\u2019 equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.abivax.com/role/Sharebasedpayments", "longName": "9952169 - Disclosure - Share-based payments", "shortName": "Share-based payments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.abivax.com/role/Financialliabilities", "longName": "9952170 - Disclosure - Financial liabilities", "shortName": "Financial liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.abivax.com/role/Retirementbenefitobligations", "longName": "9952171 - Disclosure - Retirement benefit obligations", "shortName": "Retirement benefit obligations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.abivax.com/role/Payablesandothercurrentliabilities", "longName": "9952172 - Disclosure - Payables and other current liabilities", "shortName": "Payables and other current liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.abivax.com/role/Operatingincome", "longName": "9952173 - Disclosure - Operating income", "shortName": "Operating income", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.abivax.com/role/Operatingexpenses", "longName": "9952174 - Disclosure - Operating expenses", "shortName": "Operating expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.abivax.com/role/Employees", "longName": "9952175 - Disclosure - Employees", "shortName": "Employees", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.abivax.com/role/Financialgainloss", "longName": "9952176 - Disclosure - Financial gain (loss)", "shortName": "Financial gain (loss)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.abivax.com/role/Incometax", "longName": "9952177 - Disclosure - Income tax", "shortName": "Income tax", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.abivax.com/role/Incomelosspershare", "longName": "9952178 - Disclosure - Income (loss) per share", "shortName": "Income (loss) per share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.abivax.com/role/Relatedparties", "longName": "9952179 - Disclosure - Related parties", "shortName": "Related parties", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.abivax.com/role/Offbalancesheetcommitmentsgiven", "longName": "9952180 - Disclosure - Off-balance sheet commitments given", "shortName": "Off-balance sheet commitments given", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfCommitmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfCommitmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.abivax.com/role/Offbalancesheetcommitmentsreceivedandcontingentassets", "longName": "9952181 - Disclosure - Off-balance sheet commitments received and contingent assets", "shortName": "Off-balance sheet commitments received and contingent assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.abivax.com/role/Managementandassessmentoffinancialrisks", "longName": "9952182 - Disclosure - Management and assessment of financial risks", "shortName": "Management and assessment of financial risks", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.abivax.com/role/AccountingprinciplesPolicies", "longName": "9955511 - Disclosure - Accounting principles (Policies)", "shortName": "Accounting principles (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:StatementOfIFRSCompliance", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:StatementOfIFRSCompliance", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.abivax.com/role/IntangibleassetsTables", "longName": "9955512 - Disclosure - Intangible assets (Tables)", "shortName": "Intangible assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.abivax.com/role/PropertyplantandequipmentTables", "longName": "9955513 - Disclosure - Property, plant and equipment (Tables)", "shortName": "Property, plant and equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.abivax.com/role/OtherfinancialassetsTables", "longName": "9955514 - Disclosure - Other financial assets (Tables)", "shortName": "Other financial assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.abivax.com/role/OtherreceivablesandotherassetsTables", "longName": "9955515 - Disclosure - Other receivables and other assets (Tables)", "shortName": "Other receivables and other assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "abvx:DisclosureOfDetailedInformationAboutOtherReceivablesAndOtherAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "abvx:DisclosureOfDetailedInformationAboutOtherReceivablesAndOtherAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.abivax.com/role/CashandcashequivalentsTables", "longName": "9955516 - Disclosure - Cash and cash equivalents (Tables)", "shortName": "Cash and cash equivalents (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "abvx:DisclosureOfCompositionOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "abvx:DisclosureOfCompositionOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.abivax.com/role/FinancialassetsandliabilitiesTables", "longName": "9955517 - Disclosure - Financial assets and liabilities (Tables)", "shortName": "Financial assets and liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFairValueMeasurementOfAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFairValueMeasurementOfAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.abivax.com/role/SharebasedpaymentsTables", "longName": "9955518 - Disclosure - Share-based payments (Tables)", "shortName": "Share-based payments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.abivax.com/role/FinancialliabilitiesTables", "longName": "9955519 - Disclosure - Financial liabilities (Tables)", "shortName": "Financial liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.abivax.com/role/PayablesandothercurrentliabilitiesTables", "longName": "9955520 - Disclosure - Payables and other current liabilities (Tables)", "shortName": "Payables and other current liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "abvx:DisclosureOfBreakdownOfTradeAndOtherPayablesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "abvx:DisclosureOfBreakdownOfTradeAndOtherPayablesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.abivax.com/role/OperatingincomeTables", "longName": "9955521 - Disclosure - Operating income (Tables)", "shortName": "Operating income (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "abvx:DisclosureOfDetailedInformationOfOperatingIncomeExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "abvx:DisclosureOfDetailedInformationOfOperatingIncomeExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.abivax.com/role/OperatingexpensesTables", "longName": "9955522 - Disclosure - Operating expenses (Tables)", "shortName": "Operating expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.abivax.com/role/EmployeesTables", "longName": "9955523 - Disclosure - Employees (Tables)", "shortName": "Employees (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "abvx:DisclosureOfAverageNumberOfEmployeesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "abvx:DisclosureOfAverageNumberOfEmployeesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.abivax.com/role/FinancialgainlossTables", "longName": "9955524 - Disclosure - Financial gain (loss) (Tables)", "shortName": "Financial gain (loss) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "abvx:DisclosureOfDetailedInformationAboutFinanceIncomeCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "abvx:DisclosureOfDetailedInformationAboutFinanceIncomeCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.abivax.com/role/IncomelosspershareTables", "longName": "9955525 - Disclosure - Income (loss) per share (Tables)", "shortName": "Income (loss) per share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "48", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.abivax.com/role/TheGroupDetails", "longName": "9955526 - Disclosure - The Group (Details)", "shortName": "The Group (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:Equity", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true }, "uniqueAnchor": null }, "R50": { "role": "http://www.abivax.com/role/BasisofpreparationDetails", "longName": "9955527 - Disclosure - Basis of preparation (Details)", "shortName": "Basis of preparation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProfitLoss", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-35", "name": "ifrs-full:ProceedsFromIssuingShares", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "unique": true } }, "R51": { "role": "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details", "longName": "9955528 - Disclosure - Significant events for the year ended December 31, 2024 and the three months ended March 31, 2025 and subsequent events - For the year ended 2024 (Details)", "shortName": "Significant events for the year ended December 31, 2024 and the three months ended March 31, 2025 and subsequent events - For the year ended 2024 (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-61", "name": "abvx:NumberOfFreeSharesPlansIssued", "unitRef": "plan", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-57", "name": "abvx:NumberOfADSPerOrdinaryShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "unique": true } }, "R52": { "role": "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsForthethreemonthsendedMarch312025Details", "longName": "9955529 - Disclosure - Significant events for the year ended December 31, 2024 and the three months ended March 31, 2025 and subsequent events - For the three months ended March 31, 2025 (Details)", "shortName": "Significant events for the year ended December 31, 2024 and the three months ended March 31, 2025 and subsequent events - For the three months ended March 31, 2025 (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-61", "name": "abvx:NumberOfFreeSharesPlansIssued", "unitRef": "plan", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-62", "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "unique": true } }, "R53": { "role": "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsSubsequenteventsDetails", "longName": "9955530 - Disclosure - Significant events for the year ended December 31, 2024 and the three months ended March 31, 2025 and subsequent events - Subsequent events (Details)", "shortName": "Significant events for the year ended December 31, 2024 and the three months ended March 31, 2025 and subsequent events - Subsequent events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-59", "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-60", "name": "abvx:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "unique": true } }, "R54": { "role": "http://www.abivax.com/role/SegmentinformationDetails", "longName": "9955531 - Disclosure - Segment information (Details)", "shortName": "Segment information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-70", "name": "abvx:ContributionToGroupsAssetsPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-70", "name": "abvx:ContributionToGroupsAssetsPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.abivax.com/role/GoodwillandimpairmenttestDetails", "longName": "9955532 - Disclosure - Goodwill and impairment test (Details)", "shortName": "Goodwill and impairment test (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:Goodwill", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true }, "uniqueAnchor": null }, "R56": { "role": "http://www.abivax.com/role/IntangibleassetsNarrativeDetails", "longName": "9955533 - Disclosure - Intangible assets - Narrative (Details)", "shortName": "Intangible assets - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-73", "name": "abvx:TechnologyBasedIntangibleAssetsAssetsAcquisitions", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-73", "name": "abvx:TechnologyBasedIntangibleAssetsAssetsAcquisitions", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails", "longName": "9955534 - Disclosure - Intangible assets - Disclosure of reconciliation of intangible assets (Details)", "shortName": "Intangible assets - Disclosure of reconciliation of intangible assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "unique": true } }, "R58": { "role": "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails", "longName": "9955535 - Disclosure - Property, plant and equipment - Disclosure of reconciliation of property, plant and equipment (Details)", "shortName": "Property, plant and equipment - Disclosure of reconciliation of property, plant and equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "unique": true } }, "R59": { "role": "http://www.abivax.com/role/PropertyplantandequipmentNarrativeDetails", "longName": "9955536 - Disclosure - Property, plant and equipment - Narrative (Details)", "shortName": "Property, plant and equipment - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-214", "name": "ifrs-full:RightofuseAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-214", "name": "ifrs-full:RightofuseAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails", "longName": "9955537 - Disclosure - Other financial assets - Disclosure of other financial assets (Details)", "shortName": "Other financial assets - Disclosure of other financial assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-3", "name": "abvx:NonCurrentAdvancesToCROContracts", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "abvx:NonCurrentAdvancesToCROContracts", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.abivax.com/role/OtherfinancialassetsNarrativeDetails", "longName": "9955538 - Disclosure - Other financial assets - Narrative (Details)", "shortName": "Other financial assets - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-14", "name": "abvx:DiscountRateAppliedToLongTermAdvances", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "abvx:DiscountRateAppliedToLongTermAdvances", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails", "longName": "9955539 - Disclosure - Other receivables and other assets - Disclosure of other receivables and other assets (Details)", "shortName": "Other receivables and other assets - Disclosure of other receivables and other assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-3", "name": "abvx:NonCurrentPrepaidExpenses", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "abvx:NonCurrentPrepaidExpenses", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails", "longName": "9955540 - Disclosure - Other receivables and other assets - Narrative (Details)", "shortName": "Other receivables and other assets - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-221", "name": "abvx:ProceedsFromResearchTaxCredit", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "abvx:CurrentPrepaidExpensesRelatedToCRO", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "unique": true } }, "R64": { "role": "http://www.abivax.com/role/CashandcashequivalentsDisclosureofcompositionofcashandcashequivalentsDetails", "longName": "9955541 - Disclosure - Cash and cash equivalents - Disclosure of composition of cash and cash equivalents (Details)", "shortName": "Cash and cash equivalents - Disclosure of composition of cash and cash equivalents (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:CashEquivalents", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:CashEquivalents", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.abivax.com/role/CashandcashequivalentsNarrativeDetails", "longName": "9955542 - Disclosure - Cash and cash equivalents - Narrative (Details)", "shortName": "Cash and cash equivalents - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:OtherCashAndCashEquivalents", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:OtherCashAndCashEquivalents", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "longName": "9955543 - Disclosure - Financial assets and liabilities (Details)", "shortName": "Financial assets and liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:Assets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:FinancialAssetsAtFairValue", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "unique": true } }, "R67": { "role": "http://www.abivax.com/role/ShareholdersequitySharecapitalissuedDetails", "longName": "9955544 - Disclosure - Shareholders\u2019 equity - Share capital issued (Details)", "shortName": "Shareholders\u2019 equity - Share capital issued (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:Equity", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "abvx:NumberOfTreasurySharesHeld", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "abvx:NumberOfTreasurySharesHeld", "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "unique": true } }, "R68": { "role": "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails", "longName": "9955545 - Disclosure - Shareholders\u2019 equity - Change in share capital (Details)", "shortName": "Shareholders\u2019 equity - Change in share capital (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-1", "name": "abvx:NumberOfFreeSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true }, "uniqueAnchor": null }, "R69": { "role": "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails", "longName": "9955546 - Disclosure - Share-based payments - Disclosure of reconciliation of BCEs (Details)", "shortName": "Share-based payments - Disclosure of reconciliation of BCEs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-304", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-304", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails", "longName": "9955547 - Disclosure - Share-based payments - Disclosure of reconciliation of BSAs (Details)", "shortName": "Share-based payments - Disclosure of reconciliation of BSAs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-308", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-309", "name": "ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "unique": true } }, "R71": { "role": "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "longName": "9955548 - Disclosure - Share-based payments - Narrative (Details)", "shortName": "Share-based payments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-59", "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-327", "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "unique": true } }, "R72": { "role": "http://www.abivax.com/role/SharebasedpaymentsDisclosureoffairvalueoftheBSAsatgrantdateusingtheBlackScholesmodelDetails", "longName": "9955549 - Disclosure - Share-based payments - Disclosure of fair value of the BSAs at grant date using the Black Scholes model (Details)", "shortName": "Share-based payments - Disclosure of fair value of the BSAs at grant date using the Black Scholes model (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-311", "name": "abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted", "unitRef": "eurPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-311", "name": "abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted", "unitRef": "eurPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails", "longName": "9955550 - Disclosure - Share-based payments - Disclosure of reconciliation of AGAs (Details)", "shortName": "Share-based payments - Disclosure of reconciliation of AGAs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-318", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-318", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "longName": "9955551 - Disclosure - Share-based payments - Disclosure of assumptions used for the measurement of AGAs (Details)", "shortName": "Share-based payments - Disclosure of assumptions used for the measurement of AGAs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-320", "name": "abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted", "unitRef": "eurPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "ix:continuation", "div", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-320", "name": "abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted", "unitRef": "eurPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "ix:continuation", "div", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails", "longName": "9955552 - Disclosure - Share-based payments - Disclosure of breakdown of the compensation expenses (Details)", "shortName": "Share-based payments - Disclosure of breakdown of the compensation expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails", "longName": "9955553 - Disclosure - Financial liabilities - Disclosure of financial liabilities breakdown (Details)", "shortName": "Financial liabilities - Disclosure of financial liabilities breakdown (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:NoncurrentFinancialLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:NoncurrentFinancialLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "longName": "9955554 - Disclosure - Financial liabilities - Kreos / Claret Financing (Details)", "shortName": "Financial liabilities - Kreos / Claret Financing (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-413", "name": "ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-418", "name": "ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "unique": true } }, "R78": { "role": "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails", "longName": "9955555 - Disclosure - Financial liabilities - Disclosure of the main data and assumptions, Kreos / Claret minimum return indemnifications (Details)", "shortName": "Financial liabilities - Disclosure of the main data and assumptions, Kreos / Claret minimum return indemnifications (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-382", "name": "abvx:AggregateFairValueOtherEquityInstrumentsOutstanding", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-382", "name": "abvx:AggregateFairValueOtherEquityInstrumentsOutstanding", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R79": { "role": "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails", "longName": "9955556 - Disclosure - Financial liabilities - Disclosure of the main data and assumptions, Kreos / Claret BSA (Details)", "shortName": "Financial liabilities - Disclosure of the main data and assumptions, Kreos / Claret BSA (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-427", "name": "ifrs-full:SignificantUnobservableInputLiabilities", "unitRef": "eurPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-427", "name": "ifrs-full:SignificantUnobservableInputLiabilities", "unitRef": "eurPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R80": { "role": "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails", "longName": "9955557 - Disclosure - Financial liabilities - Disclosure of the main data and assumptions, Heights convertible loan notes (Details)", "shortName": "Financial liabilities - Disclosure of the main data and assumptions, Heights convertible loan notes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-475", "name": "abvx:NumberOfConvertibleNotesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-475", "name": "abvx:NumberOfConvertibleNotesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R81": { "role": "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "longName": "9955558 - Disclosure - Financial liabilities - Heights convertible notes (Details)", "shortName": "Financial liabilities - Heights convertible notes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c-413", "name": "ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-499", "name": "ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "unique": true } }, "R82": { "role": "http://www.abivax.com/role/FinancialliabilitiesDisclosureofvariationinleaseliabilitiesDetails", "longName": "9955559 - Disclosure - Financial liabilities - Disclosure of variation in lease liabilities (Details)", "shortName": "Financial liabilities - Disclosure of variation in lease liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:LeaseLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "abvx:IncreaseInLeaseLiabilities", "unitRef": "eur", "xsiNil": "true", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "unique": true } }, "R83": { "role": "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails", "longName": "9955560 - Disclosure - Financial liabilities - Lease liabilities (Details)", "shortName": "Financial liabilities - Lease liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "c-1", "name": "abvx:ExpenseOnLeaseLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "abvx:ExpenseOnLeaseLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R84": { "role": "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails", "longName": "9955561 - Disclosure - Financial liabilities - Royalty certificates (Details)", "shortName": "Financial liabilities - Royalty certificates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:FinancialLiabilitiesAtFairValue", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-353", "name": "ifrs-full:FinancialLiabilitiesAtFairValue", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "unique": true } }, "R85": { "role": "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails", "longName": "9955562 - Disclosure - Financial liabilities - Disclosure of reconciliation of liabilities arising from financing activities (Details)", "shortName": "Financial liabilities - Disclosure of reconciliation of liabilities arising from financing activities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R86": { "role": "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails", "longName": "9955563 - Disclosure - Financial liabilities - Change in financial liabilities (Details)", "shortName": "Financial liabilities - Change in financial liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "c-4", "name": "abvx:GrossProceedsFromNonConvertibleLoansNotes", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "abvx:GrossProceedsFromNonConvertibleLoansNotes", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R87": { "role": "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails", "longName": "9955564 - Disclosure - Financial liabilities - Disclosure of changes in derivative instruments (Details)", "shortName": "Financial liabilities - Disclosure of changes in derivative instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:DerivativeFinancialLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "abvx:IssuanceOfDerivativeInstruments", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "unique": true } }, "R88": { "role": "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails", "longName": "9955565 - Disclosure - Financial liabilities - Disclosure of remaining contractual maturities of financial liabilities (Details)", "shortName": "Financial liabilities - Disclosure of remaining contractual maturities of financial liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "c-3", "name": "abvx:NonCurrentRoyaltyCertificates", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "abvx:RoyaltyCertificatesUndiscountedCashFlows", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "unique": true } }, "R89": { "role": "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureofbreakdownoftradeandotherpayablesDetails", "longName": "9955566 - Disclosure - Payables and other current liabilities - Disclosure of breakdown of trade and other payables (Details)", "shortName": "Payables and other current liabilities - Disclosure of breakdown of trade and other payables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R90": { "role": "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureoftaxandemployeerelatedpayablesDetails", "longName": "9955567 - Disclosure - Payables and other current liabilities - Disclosure of tax and employee-related payables (Details)", "shortName": "Payables and other current liabilities - Disclosure of tax and employee-related payables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:ShorttermEmployeeBenefitsAccruals", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:ShorttermEmployeeBenefitsAccruals", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R91": { "role": "http://www.abivax.com/role/OperatingincomeDisclosureofbreakdownofoperatingincomeDetails", "longName": "9955568 - Disclosure - Operating income - Disclosure of breakdown of operating income (Details)", "shortName": "Operating income - Disclosure of breakdown of operating income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "c-1", "name": "abvx:IncomeFromResearchTaxCredit", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:MiscellaneousOtherOperatingIncome", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "unique": true } }, "R92": { "role": "http://www.abivax.com/role/OperatingincomeNarrativeDetails", "longName": "9955569 - Disclosure - Operating income - Narrative (Details)", "shortName": "Operating income - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "c-1", "name": "abvx:IncomeFromResearchTaxCredit", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true }, "uniqueAnchor": null }, "R93": { "role": "http://www.abivax.com/role/OperatingexpensesDisclosureofsalesandmarketingexpensesDetails", "longName": "9955570 - Disclosure - Operating expenses - Disclosure of sales and marketing expenses (Details)", "shortName": "Operating expenses - Disclosure of sales and marketing expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:OperatingExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-620", "name": "ifrs-full:EmployeeBenefitsExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "unique": true } }, "R94": { "role": "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails", "longName": "9955571 - Disclosure - Operating expenses - Disclosure of research and development expenses (Details)", "shortName": "Operating expenses - Disclosure of research and development expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:OperatingExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-622", "name": "abvx:SubContractingStudiesAndResearchExpenses", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "unique": true } }, "R95": { "role": "http://www.abivax.com/role/OperatingexpensesNarrativeDetails", "longName": "9955572 - Disclosure - Operating expenses - Narrative (Details)", "shortName": "Operating expenses - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:OperatingExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-622", "name": "abvx:IncreaseDecreaseInOperatingExpensesCDProgram", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "unique": true } }, "R96": { "role": "http://www.abivax.com/role/OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails", "longName": "9955573 - Disclosure - Operating expenses - Disclosure of general and administrative expenses (Details)", "shortName": "Operating expenses - Disclosure of general and administrative expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:OperatingExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-624", "name": "ifrs-full:EmployeeBenefitsExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "ix:continuation", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "unique": true } }, "R97": { "role": "http://www.abivax.com/role/EmployeesDetails", "longName": "9955574 - Disclosure - Employees (Details)", "shortName": "Employees (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:AverageNumberOfEmployees", "unitRef": "employee", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:AverageNumberOfEmployees", "unitRef": "employee", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R98": { "role": "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails", "longName": "9955575 - Disclosure - Financial gain (loss) - Disclosure of net financial income (loss) (Details)", "shortName": "Financial gain (loss) - Disclosure of net financial income (loss) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "c-1", "name": "abvx:InterestExpenseOnBondsIncludingAdjustments", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "abvx:InterestExpenseOnBondsIncludingAdjustments", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R99": { "role": "http://www.abivax.com/role/FinancialgainlossNarrativeDetails", "longName": "9955576 - Disclosure - Financial gain (loss) - Narrative (Details)", "shortName": "Financial gain (loss) - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true }, "uniqueAnchor": null }, "R100": { "role": "http://www.abivax.com/role/IncomelosspershareDetails", "longName": "9955577 - Disclosure - Income (loss) per share (Details)", "shortName": "Income (loss) per share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:WeightedAverageShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "ifrs-full:EarningsPerShareExplanatory", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true }, "uniqueAnchor": null }, "R101": { "role": "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails", "longName": "9955578 - Disclosure - Off-balance sheet commitments given (Details)", "shortName": "Off-balance sheet commitments given (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "101", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:CapitalCommitments", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:CapitalCommitments", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true, "unique": true } }, "R102": { "role": "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails", "longName": "9955579 - Disclosure - Management and assessment of financial risks (Details)", "shortName": "Management and assessment of financial risks (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "102", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:OperatingExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-225", "name": "ifrs-full:OperatingExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20250331.htm", "unique": true } } }, "tag": { "abvx_A2024TaxYearMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "A2024TaxYearMember", "presentation": [ "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024, Tax Year", "label": "2024, Tax Year [Member]", "documentation": "2024, Tax Year" } } }, "auth_ref": [] }, "abvx_A2025TaxYearMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "A2025TaxYearMember", "presentation": [ "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025, Tax Year", "label": "2025, Tax Year [Member]", "documentation": "2025, Tax Year" } } }, "auth_ref": [] }, "abvx_AGA20246Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "AGA20246Member", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "AGA-2024-6", "label": "AGA-2024-6 [Member]", "documentation": "AGA-2024-6" } } }, "auth_ref": [] }, "abvx_AGA2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "AGA2024Member", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "AGA-2024", "label": "AGA-2024 [Member]", "documentation": "AGA-2024" } } }, "auth_ref": [] }, "abvx_AGA20251AGA20252AGA20253AndAGA20254Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "AGA20251AGA20252AGA20253AndAGA20254Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA-2025-1, AGA-2025-2, AGA-2025-3 and AGA-2025-4", "label": "AGA-2025-1, AGA-2025-2, AGA-2025-3 And AGA-2025-4 [Member]", "documentation": "AGA-2025-1 , AGA-2025-2, AGA-2025-3 And AGA-2025-4" } } }, "auth_ref": [] }, "abvx_AGA20251Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "AGA20251Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsForthethreemonthsendedMarch312025Details" ], "lang": { "en-us": { "role": { "terseLabel": "AGA-2025-1", "label": "AGA-2025-1 [Member]", "documentation": "AGA-2025-1" } } }, "auth_ref": [] }, "abvx_AGA20252Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "AGA20252Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsForthethreemonthsendedMarch312025Details" ], "lang": { "en-us": { "role": { "terseLabel": "AGA-2025-2", "label": "AGA-2025-2 [Member]", "documentation": "AGA-2025-2" } } }, "auth_ref": [] }, "abvx_AGA20253Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "AGA20253Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA-2025-3", "label": "AGA-2025-3 [Member]", "documentation": "AGA-2025-3" } } }, "auth_ref": [] }, "abvx_AGA20254Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "AGA20254Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA-2025-4", "label": "AGA-2025-4 [Member]", "documentation": "AGA-2025-4" } } }, "auth_ref": [] }, "abvx_AGA20255Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "AGA20255Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsForthethreemonthsendedMarch312025Details" ], "lang": { "en-us": { "role": { "terseLabel": "AGA-2025-5", "label": "AGA-2025-5 [Member]", "documentation": "AGA-2025-5" } } }, "auth_ref": [] }, "abvx_AGA2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "AGA2025Member", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsForthethreemonthsendedMarch312025Details" ], "lang": { "en-us": { "role": { "terseLabel": "AGA-2025", "label": "AGA-2025 [Member]", "documentation": "AGA-2025" } } }, "auth_ref": [] }, "abvx_AccountingPrinciplesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "AccountingPrinciplesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Principles [Abstract]", "label": "Accounting Principles [Abstract]", "documentation": "Accounting Principles [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_AccrualsClassifiedAsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AccrualsClassifiedAsCurrent", "crdr": "credit", "calculation": { "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureofbreakdownoftradeandotherpayablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureofbreakdownoftradeandotherpayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued invoices", "label": "Accruals classified as current" } }, "en": { "role": { "documentation": "The amount of accruals classified as current. [Refer: Accruals]" } } }, "auth_ref": [ "r229" ] }, "ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AccumulatedDepreciationAmortisationAndImpairmentMember", "presentation": [ "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AMORTIZATION", "label": "Accumulated depreciation, amortisation and impairment [member]" } }, "en": { "role": { "documentation": "This member stands for accumulated depreciation, amortisation and impairment. [Refer: Impairment loss; Depreciation and amortisation expense]" } } }, "auth_ref": [ "r39", "r43", "r62", "r73", "r76" ] }, "ifrs-full_AccumulatedDepreciationAndAmortisationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AccumulatedDepreciationAndAmortisationMember", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "DEPRECIATION", "label": "Accumulated depreciation and amortisation [member]" } }, "en": { "role": { "documentation": "This member stands for accumulated depreciation and amortisation. [Refer: Depreciation and amortisation expense]" } } }, "auth_ref": [ "r43", "r232", "r237", "r239", "r240" ] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition", "label": "Additions other than through business combinations, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r63" ] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition", "label": "Additions other than through business combinations, property, plant and equipment" } }, "en": { "role": { "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]" } } }, "auth_ref": [ "r40" ] }, "ifrs-full_AdjustedWeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustedWeightedAverageShares", "presentation": [ "http://www.abivax.com/role/IncomelosspershareDetails", "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFLOSS" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average number of outstanding shares used for computing diluted loss per share (in shares)", "terseLabel": "Weighted average number of outstanding shares, diluted loss per share (in shares)", "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share" } }, "en": { "role": { "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r53" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease (increase) in other receivables and other assets", "label": "Adjustments for decrease (increase) in trade and other receivables" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]" } } }, "auth_ref": [ "r244" ] }, "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustmentsForDepreciationAndAmortisationExpense", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Elimination of amortization of intangibles and depreciation of property, plant and equipment", "label": "Adjustments for depreciation and amortisation expense" } }, "en": { "role": { "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]" } } }, "auth_ref": [ "r243" ] }, "ifrs-full_AdjustmentsForFairValueGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustmentsForFairValueGainsLosses", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease in derivatives and liabilities fair value", "label": "Adjustments for fair value losses (gains)" } }, "en": { "role": { "documentation": "Adjustments for fair value losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r243" ] }, "abvx_AdjustmentsForIncreaseDecreaseInDeferredIncomeAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "AdjustmentsForIncreaseDecreaseInDeferredIncomeAndOtherLiabilities", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in deferred income and other liabilities", "label": "Adjustments For Increase (Decrease) In Deferred Income And Other Liabilities", "documentation": "Adjustments For Increase (Decrease) In Deferred Income And Other Liabilities" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Elimination of retirement benefit obligations", "label": "Adjustments for increase (decrease) in employee benefit liabilities" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in employee benefit liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r244" ] }, "abvx_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in tax and social security liabilities", "label": "Adjustments For Increase (Decrease) In Tax And Social Security Liabilities", "documentation": "Adjustments For Increase (Decrease) In Tax And Social Security Liabilities" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in trade payables", "label": "Adjustments for increase (decrease) in trade accounts payable" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r242" ] }, "abvx_AdjustmentsForNetGainOnSaleOfTreasuryShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "AdjustmentsForNetGainOnSaleOfTreasuryShares", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Net gain on sale of treasury shares", "label": "Adjustments For Net Gain On Sale Of Treasury Shares", "documentation": "Adjustments For Net Gain On Sale Of Treasury Shares" } } }, "auth_ref": [] }, "abvx_AdjustmentsForOtherFinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "AdjustmentsForOtherFinanceCosts", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expenses and other financial expenses", "label": "Adjustments For Other Finance Costs", "documentation": "Adjustments For Other Finance Costs" } } }, "auth_ref": [] }, "abvx_AdjustmentsForOtherFinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "AdjustmentsForOtherFinanceIncome", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Financial income", "label": "Adjustments For Other Finance Income", "documentation": "Adjustments For Other Finance Income" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustmentsForReconcileProfitLossAbstract", "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments for:", "label": "Adjustments to reconcile profit (loss) [abstract]" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForSharebasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustmentsForSharebasedPayments", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Elimination of share-based compensation expenses", "label": "Adjustments for share-based payments" } }, "en": { "role": { "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r243" ] }, "abvx_AdjustmentsForUnwindingOfDiscountRelatedToConditionalAdvances": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "AdjustmentsForUnwindingOfDiscountRelatedToConditionalAdvances", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of unwinding the discount related to advances", "label": "Adjustments For Unwinding Of Discount Related To Conditional Advances", "documentation": "Adjustments For Unwinding Of Discount Related To Conditional Advances" } } }, "auth_ref": [] }, "abvx_AdvancesReimbursedByMadeToContractResearchOrganizations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "AdvancesReimbursedByMadeToContractResearchOrganizations", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/OtherfinancialassetsNarrativeDetails", "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Advances reimbursed by (made to) CROs", "label": "Advances Reimbursed By (Made To) Contract Research Organizations", "documentation": "Advances Reimbursed By (Made To) Contract Research Organizations" } } }, "auth_ref": [] }, "abvx_AggregateFairValueConvertibleNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "AggregateFairValueConvertibleNotes", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of convertible notes", "label": "Aggregate Fair Value, Convertible Notes", "documentation": "Aggregate Fair Value, Convertible Notes" } } }, "auth_ref": [] }, "abvx_AggregateFairValueOtherEquityInstrumentsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "AggregateFairValueOtherEquityInstrumentsOutstanding", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of other equity instruments", "label": "Aggregate Fair Value, Other Equity Instruments Outstanding", "documentation": "Aggregate Fair Value, Other Equity Instruments Outstanding" } } }, "auth_ref": [] }, "currency_AllCurrenciesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2024", "localname": "AllCurrenciesDomain", "presentation": [ "http://www.abivax.com/role/CashandcashequivalentsNarrativeDetails", "http://www.abivax.com/role/FinancialgainlossNarrativeDetails", "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All Currencies [Domain]", "label": "All Currencies [Domain]" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AmortisationIntangibleAssetsOtherThanGoodwill", "presentation": [ "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Increase", "label": "Amortisation, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r66" ] }, "abvx_AmortizedCostEIRMethodMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "AmortizedCostEIRMethodMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortized cost (EIR method)", "label": "Amortized Cost (EIR Method) [Member]", "documentation": "Amortized Cost (EIR Method)" } } }, "auth_ref": [] }, "abvx_AmountOfReasonablyPossibleDecreaseInUnobservableInputLiabilities": { "xbrltype": "perShareItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "AmountOfReasonablyPossibleDecreaseInUnobservableInputLiabilities", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Amount of reasonably possible decrease in unobservable input, liabilities", "label": "Amount Of Reasonably Possible Decrease In Unobservable Input, Liabilities", "documentation": "Amount Of Reasonably Possible Decrease In Unobservable Input, Liabilities" } } }, "auth_ref": [] }, "abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities": { "xbrltype": "perShareItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of reasonably possible increase in unobservable input, liabilities", "label": "Amount Of Reasonably Possible Increase In Unobservable Input, Liabilities", "documentation": "Amount Of Reasonably Possible Increase In Unobservable Input, Liabilities" } } }, "auth_ref": [] }, "ifrs-full_Assets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "terseLabel": "Financial assets", "label": "Assets" } }, "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r15", "r102", "r103", "r105", "r162", "r164" ] }, "ifrs-full_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AssetsAbstract", "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [abstract]" } } }, "auth_ref": [] }, "abvx_AssetsAcquisitionsAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "AssetsAcquisitionsAxis", "presentation": [ "http://www.abivax.com/role/IntangibleassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets Acquisitions [Axis]", "label": "Assets Acquisitions [Axis]", "documentation": "Assets Acquisitions" } } }, "auth_ref": [] }, "abvx_AssetsAcquisitionsDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "AssetsAcquisitionsDomain", "presentation": [ "http://www.abivax.com/role/IntangibleassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets Acquisitions [Domain]", "label": "Assets Acquisitions [Domain]", "documentation": "Assets Acquisitions [Domain]" } } }, "auth_ref": [] }, "abvx_AtTheMarketATMProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "AtTheMarketATMProgramMember", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "At-The-Market (ATM) Program", "label": "At-The-Market (ATM) Program [Member]", "documentation": "At-The-Market (ATM) Program" } } }, "auth_ref": [] }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis", "presentation": [ "http://www.abivax.com/role/OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails", "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails", "http://www.abivax.com/role/OperatingexpensesDisclosureofsalesandmarketingexpensesDetails", "http://www.abivax.com/role/OperatingexpensesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Attribution of expenses by nature to their function [axis]", "label": "Attribution of expenses by nature to their function [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r221", "r224" ] }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AttributionOfExpensesByNatureToTheirFunctionDomain", "presentation": [ "http://www.abivax.com/role/OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails", "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails", "http://www.abivax.com/role/OperatingexpensesDisclosureofsalesandmarketingexpensesDetails", "http://www.abivax.com/role/OperatingexpensesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Attribution of expenses by nature to their function [domain]", "label": "Attribution of expenses by nature to their function [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value of the \u2018Attribution of expenses by nature to their function' axis if no other member is used." } } }, "auth_ref": [ "r221", "r224" ] }, "ifrs-full_AverageNumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AverageNumberOfEmployees", "presentation": [ "http://www.abivax.com/role/EmployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average number of employees", "label": "Average number of employees" } }, "en": { "role": { "documentation": "The average number of personnel employed by the entity during a period." } } }, "auth_ref": [ "r224" ] }, "abvx_BSA20241Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "BSA20241Member", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "BSA-2024-1", "label": "BSA-2024-1 [Member]", "documentation": "BSA-2024-1" } } }, "auth_ref": [] }, "abvx_BSA20251Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "BSA20251Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureoffairvalueoftheBSAsatgrantdateusingtheBlackScholesmodelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA-2025-1", "label": "BSA-2025-1 [Member]", "documentation": "BSA-2025-1" } } }, "auth_ref": [] }, "abvx_BSA20252Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "BSA20252Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureoffairvalueoftheBSAsatgrantdateusingtheBlackScholesmodelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA-2025-2", "label": "BSA-2025-2 [Member]", "documentation": "BSA-2025-2" } } }, "auth_ref": [] }, "ifrs-full_BankBorrowingsUndiscountedCashFlows": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "BankBorrowingsUndiscountedCashFlows", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": "abvx_FinancialLiabilitiesUndiscountedCashFlows", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, undiscounted cash flows", "label": "Bank borrowings, undiscounted cash flows" } }, "en": { "role": { "documentation": "The amount of contractual undiscounted cash flows in relation to bank borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r212", "r215" ] }, "abvx_BanquePubliqueDInvestissementBPIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "BanquePubliqueDInvestissementBPIMember", "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BPI", "label": "Banque Publique d\u2019Investissement (BPI) [Member]", "documentation": "Banque Publique d\u2019Investissement (BPI)" } } }, "auth_ref": [] }, "ifrs-full_BasicEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "BasicEarningsLossPerShare", "presentation": [ "http://www.abivax.com/role/IncomelosspershareDetails", "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFLOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Basic loss per share (in euro per share)", "label": "Basic earnings (loss) per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } } }, "auth_ref": [ "r51", "r52" ] }, "abvx_BoardMemberMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "BoardMemberMember", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Board Member", "label": "Board Member [Member]", "documentation": "Board Member" } } }, "auth_ref": [] }, "ifrs-full_Borrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "Borrowings", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings", "label": "Borrowings" } }, "en": { "role": { "documentation": "The amount of outstanding funds that the entity is obligated to repay." } } }, "auth_ref": [ "r226" ] }, "ifrs-full_BorrowingsByNameAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "BorrowingsByNameAxis", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings by name [axis]", "label": "Borrowings by name [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r250" ] }, "ifrs-full_BorrowingsByNameDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "BorrowingsByNameDomain", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings by name [domain]", "label": "Borrowings by name [domain]" } }, "en": { "role": { "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]" } } }, "auth_ref": [ "r250" ] }, "abvx_BorrowingsMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "BorrowingsMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, maximum borrowing capacity", "label": "Borrowings, Maximum Borrowing Capacity", "documentation": "Borrowings, Maximum Borrowing Capacity" } } }, "auth_ref": [] }, "abvx_BorrowingsMaximumBorrowingCapacityPerTranche": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "BorrowingsMaximumBorrowingCapacityPerTranche", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, maximum borrowing capacity per tranche", "label": "Borrowings, Maximum Borrowing Capacity Per Tranche", "documentation": "Borrowings, Maximum Borrowing Capacity Per Tranche" } } }, "auth_ref": [] }, "abvx_BorrowingsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "BorrowingsMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings", "label": "Borrowings [Member]", "documentation": "Borrowings" } } }, "auth_ref": [] }, "abvx_BorrowingsNumberOfTranches": { "xbrltype": "integerItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "BorrowingsNumberOfTranches", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, number of tranches", "label": "Borrowings, Number Of Tranches", "documentation": "Borrowings, Number Of Tranches" } } }, "auth_ref": [] }, "ifrs-full_BottomOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "BottomOfRangeMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/OtherfinancialassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bottom of range", "label": "Bottom of range [member]" } }, "en": { "role": { "documentation": "This member stands for the bottom of a range." } } }, "auth_ref": [ "r86", "r108", "r121", "r129", "r200", "r202", "r250" ] }, "ifrs-full_BuildingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "BuildingsMember", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails", "http://www.abivax.com/role/PropertyplantandequipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BUILDINGS", "verboseLabel": "Buildings", "label": "Buildings [member]" } }, "en": { "role": { "documentation": "This member stands for a class of plant, property and equipment representing depreciable buildings and similar structures for use in operations. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r231" ] }, "abvx_CARENAConditionalAdvanceBPIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "CARENAConditionalAdvanceBPIMember", "presentation": [ "http://www.abivax.com/role/OperatingincomeNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "CARENA conditional advance", "label": "CARENA Conditional Advance, BPI [Member]", "documentation": "CARENA Conditional Advance, BPI" } } }, "auth_ref": [] }, "abvx_CIRTaxYearAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "CIRTaxYearAxis", "presentation": [ "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CIR Tax Year [Axis]", "label": "CIR Tax Year [Axis]", "documentation": "CIR Tax Year" } } }, "auth_ref": [] }, "abvx_CIRTaxYearDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "CIRTaxYearDomain", "presentation": [ "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CIR Tax Year [Domain]", "label": "CIR Tax Year [Domain]", "documentation": "CIR Tax Year [Domain]" } } }, "auth_ref": [] }, "ifrs-full_CapitalCommitments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CapitalCommitments", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital commitments", "label": "Capital commitments" } }, "en": { "role": { "documentation": "The amount of future capital expenditures that the entity is committed to make." } } }, "auth_ref": [ "r224" ] }, "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis", "presentation": [ "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails", "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]", "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r39", "r41", "r62", "r67", "r72", "r73", "r74", "r75", "r76", "r134", "r143", "r144" ] }, "ifrs-full_CarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CarryingAmountMember", "presentation": [ "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails", "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying amount [member]", "label": "Carrying amount [member]" } }, "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]" } } }, "auth_ref": [ "r41", "r67", "r72", "r74", "r75", "r134", "r143", "r144" ] }, "ifrs-full_Cash": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "Cash", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CashandcashequivalentsDisclosureofcompositionofcashandcashequivalentsDetails": { "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/CashandcashequivalentsDisclosureofcompositionofcashandcashequivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Cash" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]" } } }, "auth_ref": [ "r245" ] }, "ifrs-full_CashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 3.0 }, "http://www.abivax.com/role/CashandcashequivalentsDisclosureofcompositionofcashandcashequivalentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails", "http://www.abivax.com/role/CashandcashequivalentsDisclosureofcompositionofcashandcashequivalentsDetails", "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "periodStartLabel": "Cash and cash equivalents at the beginning of the period", "periodEndLabel": "Cash and cash equivalents at the end of the period", "totalLabel": "Cash and cash equivalents", "label": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } } }, "auth_ref": [ "r13", "r87", "r99" ] }, "ifrs-full_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "label": "Cash and cash equivalents [abstract]" } } }, "auth_ref": [] }, "abvx_CashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "CashAndCashEquivalentsMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash And Cash Equivalents [Member]", "documentation": "Cash And Cash Equivalents" } } }, "auth_ref": [] }, "ifrs-full_CashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CashEquivalents", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CashandcashequivalentsDisclosureofcompositionofcashandcashequivalentsDetails": { "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/CashandcashequivalentsDisclosureofcompositionofcashandcashequivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash equivalents" } }, "en": { "role": { "documentation": "The amount of short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value." } } }, "auth_ref": [ "r245" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Cash flows provided by (used in) financing activities", "label": "Cash flows from (used in) financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations." } } }, "auth_ref": [ "r77", "r88" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows provided by financing activities", "label": "Cash flows from (used in) financing activities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Cash flows provided by investing activities", "label": "Cash flows from (used in) investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations." } } }, "auth_ref": [ "r77", "r88" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows used in investing activities", "label": "Cash flows from (used in) investing activities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivities", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Cash flows used in operating activities", "label": "Cash flows from (used in) operating activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities, from continuing and discontinued operations. [Refer: Revenue]" } } }, "auth_ref": [ "r77", "r88" ] }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows used in operating activities", "label": "Cash flows from (used in) operating activities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Cash flows used in operating activities before change in working capital requirements", "label": "Cash flows from (used in) operations before changes in working capital" } }, "en": { "role": { "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital." } } }, "auth_ref": [ "r191", "r244" ] }, "abvx_CashPaymentsForDepositsAndOtherFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "CashPaymentsForDepositsAndOtherFinancialAssets", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Increase in Deposits and other financial assets", "label": "Cash Payments For Deposits And Other Financial Assets", "documentation": "Cash Payments For Deposits And Other Financial Assets" } } }, "auth_ref": [] }, "ifrs-full_CategoriesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CategoriesOfFinancialAssetsAxis", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Categories of financial assets [axis]", "label": "Categories of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r157" ] }, "ifrs-full_CategoriesOfFinancialAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CategoriesOfFinancialAssetsDomain", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Categories of financial assets [domain]", "label": "Categories of financial assets [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r157" ] }, "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CategoriesOfFinancialLiabilitiesAxis", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Categories of financial liabilities [axis]", "label": "Categories of financial liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r157" ] }, "ifrs-full_CategoriesOfFinancialLiabilitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CategoriesOfFinancialLiabilitiesDomain", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Categories of financial liabilities [domain]", "label": "Categories of financial liabilities [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r157" ] }, "ifrs-full_ChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ChangesInEquityAbstract", "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in equity [abstract]", "label": "Changes in equity [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ClassesOfAssetsAxis", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/PropertyplantandequipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of assets [axis]", "label": "Classes of assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r55", "r56", "r107", "r115" ] }, "ifrs-full_ClassesOfAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ClassesOfAssetsDomain", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/PropertyplantandequipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of assets [domain]", "label": "Classes of assets [domain]" } }, "en": { "role": { "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used." } } }, "auth_ref": [ "r55", "r107", "r115" ] }, "ifrs-full_ClassesOfFinancialLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ClassesOfFinancialLiabilitiesAxis", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails", "http://www.abivax.com/role/OperatingincomeNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial liabilities [axis]", "label": "Classes of financial liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r150", "r151", "r169", "r170" ] }, "ifrs-full_ClassesOfFinancialLiabilitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ClassesOfFinancialLiabilitiesDomain", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails", "http://www.abivax.com/role/OperatingincomeNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial liabilities [domain]", "label": "Classes of financial liabilities [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r150", "r151", "r169", "r170" ] }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis", "presentation": [ "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of intangible assets other than goodwill [axis]", "label": "Classes of intangible assets other than goodwill [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r68" ] }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillDomain", "presentation": [ "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets other than goodwill [member]", "label": "Classes of intangible assets other than goodwill [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used." } } }, "auth_ref": [ "r68" ] }, "ifrs-full_ClassesOfLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ClassesOfLiabilitiesAxis", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of liabilities [axis]", "label": "Classes of liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r107" ] }, "ifrs-full_ClassesOfLiabilitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ClassesOfLiabilitiesDomain", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of liabilities [domain]", "label": "Classes of liabilities [domain]" } }, "en": { "role": { "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]" } } }, "auth_ref": [ "r107" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of property, plant and equipment [axis]", "label": "Classes of property, plant and equipment [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r42" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentDomain", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of property, plant and equipment [domain]", "label": "Classes of property, plant and equipment [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Classes of property, plant and equipment' axis if no other member is used." } } }, "auth_ref": [ "r42" ] }, "abvx_CollaborationAgreementsDevelopmentMilestonePaymentPhase2": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "CollaborationAgreementsDevelopmentMilestonePaymentPhase2", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/IntangibleassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration agreements, development milestone payment, Phase 2", "label": "Collaboration Agreements, Development Milestone Payment, Phase 2", "documentation": "Collaboration Agreements, Development Milestone Payment, Phase 2" } } }, "auth_ref": [] }, "ifrs-full_ComponentsOfEquityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ComponentsOfEquityAxis", "presentation": [ "http://www.abivax.com/role/ShareholdersequitySharecapitalissuedDetails", "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Components of equity [axis]", "label": "Components of equity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r6" ] }, "ifrs-full_ComponentsOfEquityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ComponentsOfEquityDomain", "presentation": [ "http://www.abivax.com/role/ShareholdersequitySharecapitalissuedDetails", "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Components of equity [domain]", "label": "Components of equity [domain]" } }, "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "auth_ref": [ "r6" ] }, "ifrs-full_ComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ComprehensiveIncome", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Total comprehensive loss for the period", "label": "Comprehensive income" } }, "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } } }, "auth_ref": [ "r1", "r29", "r90", "r92", "r97", "r193" ] }, "ifrs-full_ComputerSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ComputerSoftwareMember", "presentation": [ "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SOFTWARES", "label": "Computer software [member]" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r183" ] }, "abvx_ConditionalAdvances": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "ConditionalAdvances", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Conditional advances", "label": "Conditional Advances", "documentation": "Conditional Advances" } } }, "auth_ref": [] }, "abvx_ConditionalAdvancesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "ConditionalAdvancesMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conditional advances Bpifrance", "label": "Conditional Advances [Member]", "documentation": "Conditional Advances" } } }, "auth_ref": [] }, "abvx_ContributionToGroupsAssetsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "ContributionToGroupsAssetsPercentage", "presentation": [ "http://www.abivax.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contribution to Group's assets, percentage", "label": "Contribution To Group's Assets, Percentage", "documentation": "Contribution To Group's Assets, Percentage" } } }, "auth_ref": [] }, "abvx_ContributionToGroupsLiabilitiesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "ContributionToGroupsLiabilitiesPercentage", "presentation": [ "http://www.abivax.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contribution to Group's liabilities, percentage", "label": "Contribution To Group's Liabilities, Percentage", "documentation": "Contribution To Group's Liabilities, Percentage" } } }, "auth_ref": [] }, "abvx_ContributionToGroupsNetProfitsLossesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "ContributionToGroupsNetProfitsLossesPercentage", "presentation": [ "http://www.abivax.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contribution to Group's net profits (losses), percentage", "label": "Contribution To Group's Net Profits (Losses), Percentage", "documentation": "Contribution To Group's Net Profits (Losses), Percentage" } } }, "auth_ref": [] }, "abvx_ConversionPricePerShareMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "ConversionPricePerShareMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion price per share (in euro per share)", "label": "Conversion Price Per Share, Measurement Input [Member]", "documentation": "Conversion Price Per Share, Measurement Input" } } }, "auth_ref": [] }, "abvx_ConvertibleLoansNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "ConvertibleLoansNotes", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible loans notes", "label": "Convertible Loans Notes", "documentation": "Convertible Loans Notes" } } }, "auth_ref": [] }, "abvx_ConvertibleLoansNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "ConvertibleLoansNotesMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible loan notes", "label": "Convertible Loans Notes [Member]", "documentation": "Convertible Loans Notes" } } }, "auth_ref": [] }, "abvx_ConvertibleLoansNotesUndiscountedCashFlows": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "ConvertibleLoansNotesUndiscountedCashFlows", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": "abvx_FinancialLiabilitiesUndiscountedCashFlows", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible loans notes, undiscounted cash flows", "label": "Convertible Loans Notes, Undiscounted Cash Flows", "documentation": "Convertible Loans Notes, Undiscounted Cash Flows" } } }, "auth_ref": [] }, "ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember", "presentation": [ "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PATENTS", "label": "Copyrights, patents and other industrial property rights, service and operating rights [member]" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets representing copyrights, patents and other industrial property rights, service and operating rights. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r184" ] }, "ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CorporateInformationAndStatementOfIFRSComplianceAbstract", "lang": { "en-us": { "role": { "label": "Corporate information and statement of IFRS compliance [abstract]" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "ifrs-full_CreditSpreadMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CreditSpreadMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit spread", "label": "Credit spread, measurement input [member]" } }, "en": { "role": { "documentation": "This member stands for the credit spread used as a measurement input." } } }, "auth_ref": [ "r246" ] }, "srt_CurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CurrencyAxis", "presentation": [ "http://www.abivax.com/role/CashandcashequivalentsNarrativeDetails", "http://www.abivax.com/role/FinancialgainlossNarrativeDetails", "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency [Axis]", "label": "Currency [Axis]" } } }, "auth_ref": [] }, "ifrs-full_CurrencyRiskMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrencyRiskMember", "presentation": [ "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency risk", "label": "Currency risk [member]" } }, "en": { "role": { "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r122", "r123", "r124", "r125", "r158" ] }, "abvx_CurrentAdvancesToCROContracts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "CurrentAdvancesToCROContracts", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails": { "parentTag": "ifrs-full_OtherCurrentFinancialAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advances related to CRO contracts", "label": "Current Advances To CRO Contracts", "documentation": "Current Advances To CRO Contracts" } } }, "auth_ref": [] }, "ifrs-full_CurrentAdvancesToSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentAdvancesToSuppliers", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current advances to suppliers", "label": "Current advances to suppliers" } }, "en": { "role": { "documentation": "The amount of current advances made to suppliers before goods or services are received." } } }, "auth_ref": [ "r224" ] }, "ifrs-full_CurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentAssets", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Current assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } } }, "auth_ref": [ "r18", "r93", "r193" ] }, "ifrs-full_CurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentAssetsAbstract", "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Current assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CurrentDerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentDerivativeFinancialLiabilities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative instruments", "label": "Current derivative financial liabilities" } }, "en": { "role": { "documentation": "The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r226" ] }, "ifrs-full_CurrentFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentFinancialLiabilities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Current financial liabilities", "label": "Current financial liabilities" } }, "en": { "role": { "documentation": "The amount of current financial liabilities. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r139" ] }, "abvx_CurrentFinancialLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "CurrentFinancialLiabilitiesMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities-current portion", "label": "Current Financial Liabilities [Member]", "documentation": "Current Financial Liabilities" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ifrs-full_CurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentLiabilities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } } }, "auth_ref": [ "r19", "r95", "r193" ] }, "ifrs-full_CurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentLiabilitiesAbstract", "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Current liabilities [abstract]" } } }, "auth_ref": [] }, "abvx_CurrentPayablesOnOtherTaxAndRelatedPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "CurrentPayablesOnOtherTaxAndRelatedPayments", "crdr": "credit", "calculation": { "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureoftaxandemployeerelatedpayablesDetails": { "parentTag": "abvx_CurrentTaxAndEmployeeBenefitLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureoftaxandemployeerelatedpayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other tax and related payments", "label": "Current Payables On Other Tax And Related Payments", "documentation": "Current Payables On Other Tax And Related Payments" } } }, "auth_ref": [] }, "ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax", "crdr": "credit", "calculation": { "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureoftaxandemployeerelatedpayablesDetails": { "parentTag": "abvx_CurrentTaxAndEmployeeBenefitLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureoftaxandemployeerelatedpayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Social security and other", "label": "Current payables on social security and taxes other than income tax" } }, "en": { "role": { "documentation": "The amount of current payables on social security and taxes other than incomes tax. [Refer: Payables on social security and taxes other than income tax]" } } }, "auth_ref": [ "r229" ] }, "abvx_CurrentPortionOfNonCurrentConvertibleLoansNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "CurrentPortionOfNonCurrentConvertibleLoansNotes", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible loan notes", "label": "Current Portion Of Non-Current Convertible Loans Notes", "documentation": "Current Portion Of Non-Current Convertible Loans Notes" } } }, "auth_ref": [] }, "ifrs-full_CurrentPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentPrepaidExpenses", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails": { "parentTag": "abvx_CurrentReceivablesAndCurrentPrepaidExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "label": "Current prepaid expenses" } }, "en": { "role": { "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised." } } }, "auth_ref": [ "r224" ] }, "abvx_CurrentPrepaidExpensesRelatedToCRO": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "CurrentPrepaidExpensesRelatedToCRO", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current prepaid expenses related to CRO", "label": "Current Prepaid Expenses Related To CRO", "documentation": "Current Prepaid Expenses Related To CRO" } } }, "auth_ref": [] }, "abvx_CurrentReceivablesAndCurrentPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "CurrentReceivablesAndCurrentPrepaidExpenses", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails": { "parentTag": "ifrs-full_OtherAssets", "weight": 1.0, "order": 1.0 }, "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails", "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables and assets", "totalLabel": "Total current other receivables and assets", "label": "Current Receivables And Current Prepaid Expenses", "documentation": "Current Receivables And Current Prepaid Expenses" } } }, "auth_ref": [] }, "abvx_CurrentReceivablesFromCreditNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "CurrentReceivablesFromCreditNotes", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails": { "parentTag": "abvx_CurrentReceivablesAndCurrentPrepaidExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit notes", "label": "Current Receivables From Credit Notes", "documentation": "Current Receivables From Credit Notes" } } }, "auth_ref": [] }, "abvx_CurrentResearchTaxCreditReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "CurrentResearchTaxCreditReceivables", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails": { "parentTag": "abvx_CurrentReceivablesAndCurrentPrepaidExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails", "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research tax credit (\"CIR\")", "label": "Current Research Tax Credit Receivables", "documentation": "Current Research Tax Credit Receivables" } } }, "auth_ref": [] }, "abvx_CurrentTaxAndEmployeeBenefitLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "CurrentTaxAndEmployeeBenefitLiabilities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 6.0 }, "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureoftaxandemployeerelatedpayablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureoftaxandemployeerelatedpayablesDetails", "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Tax and employee-related payables", "totalLabel": "Tax and employee-related payables", "label": "Current Tax And Employee Benefit Liabilities", "documentation": "Current Tax And Employee Benefit Liabilities" } } }, "auth_ref": [] }, "ifrs-full_CurrentValueAddedTaxReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentValueAddedTaxReceivables", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails": { "parentTag": "abvx_CurrentReceivablesAndCurrentPrepaidExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "VAT receivables", "label": "Current value added tax receivables" } }, "en": { "role": { "documentation": "The amount of current value added tax receivables. [Refer: Value added tax receivables]" } } }, "auth_ref": [ "r227" ] }, "abvx_DecreaseInLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "DecreaseInLeaseLiabilities", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofvariationinleaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease", "label": "Decrease In Lease Liabilities", "documentation": "Decrease In Lease Liabilities" } } }, "auth_ref": [] }, "abvx_DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest paid", "label": "Decrease Through Interest Paid, Liabilities Arising From Financing Activities", "documentation": "Decrease Through Interest Paid, Liabilities Arising From Financing Activities" } } }, "auth_ref": [] }, "abvx_DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayments", "label": "Decrease Through Repayments, Liabilities Arising From Financing Activities", "documentation": "Decrease Through Repayments, Liabilities Arising From Financing Activities" } } }, "auth_ref": [] }, "abvx_DepreciationExpenseLease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "DepreciationExpenseLease", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation expense, lease", "label": "Depreciation Expense, Lease", "documentation": "Depreciation Expense, Lease" } } }, "auth_ref": [] }, "ifrs-full_DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Increase", "label": "Depreciation, property, plant and equipment including right-of-use assets" } }, "en": { "role": { "documentation": "The amount of depreciation of property, plant and equipment including right-of-use assets. [Refer: Depreciation and amortisation expense; Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r233" ] }, "ifrs-full_DerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DerivativeFinancialLiabilities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Derivative financial liabilities at beginning of period", "periodEndLabel": "Derivative financial liabilities at end of period", "terseLabel": "Derivative instruments", "label": "Derivative financial liabilities" } }, "en": { "role": { "documentation": "The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r226" ] }, "ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DerivativeFinancialLiabilitiesUndiscountedCashFlows", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": "abvx_FinancialLiabilitiesUndiscountedCashFlows", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative financial liabilities, undiscounted cash flows", "label": "Derivative financial liabilities, undiscounted cash flows" } }, "en": { "role": { "documentation": "The amount of contractual undiscounted cash flows in relation to derivative financial liabilities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r148" ] }, "ifrs-full_DerivativesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DerivativesMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative instruments", "label": "Derivatives [member]" } }, "en": { "role": { "documentation": "This member stands for financial instruments or other contracts within the scope of IFRS 9 with all three of the following characteristics: (a) Their value changes in response to the change in a specified interest rate, financial instrument price, commodity price, foreign exchange rate, index of prices or rates, credit rating or credit index, or other variable, provided in the case of a non-financial variable that the variable is not specific to a party to the contract (sometimes called the \u2018underlying\u2019); (b) They require no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; (c) They are settled at a future date. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r195", "r201", "r209", "r216" ] }, "abvx_DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Going concern", "label": "Description Of Accounting Policy For Going Concern [Policy Text Block]", "documentation": "Description Of Accounting Policy For Going Concern" } } }, "auth_ref": [] }, "ifrs-full_DilutedEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DilutedEarningsLossPerShare", "presentation": [ "http://www.abivax.com/role/IncomelosspershareDetails", "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFLOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted loss per share (in euro per share)", "label": "Diluted earnings (loss) per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r51", "r52" ] }, "abvx_DisclosureOfAccountingPolicyForAccountingJudgementsAndEstimatesExplanatoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "DisclosureOfAccountingPolicyForAccountingJudgementsAndEstimatesExplanatoryPolicyTextBlock", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of judgments and estimates", "label": "Disclosure Of Accounting Policy For Accounting Judgements And Estimates Explanatory [Policy Text Block]", "documentation": "Disclosure Of Accounting Policy For Accounting Judgements And Estimates Explanatory" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems", "presentation": [ "http://www.abivax.com/role/OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails", "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails", "http://www.abivax.com/role/OperatingexpensesDisclosureofsalesandmarketingexpensesDetails", "http://www.abivax.com/role/OperatingexpensesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of attribution of expenses by nature to their function [line items]", "label": "Disclosure of attribution of expenses by nature to their function [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable", "presentation": [ "http://www.abivax.com/role/OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails", "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails", "http://www.abivax.com/role/OperatingexpensesDisclosureofsalesandmarketingexpensesDetails", "http://www.abivax.com/role/OperatingexpensesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of attribution of expenses by nature to their function [table]", "label": "Disclosure of attribution of expenses by nature to their function [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to attribution of expenses by nature to analysis of expenses by function in the statement of profit or loss." } } }, "auth_ref": [ "r221", "r224" ] }, "abvx_DisclosureOfAverageNumberOfEmployeesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "DisclosureOfAverageNumberOfEmployeesTableTextBlock", "presentation": [ "http://www.abivax.com/role/EmployeesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of average workforce during the periods", "label": "Disclosure Of Average Number Of Employees [Table Text Block]", "documentation": "Disclosure Of Average Number Of Employees" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "presentation": [ "http://www.abivax.com/role/Basisofpreparation" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of preparation", "label": "Disclosure of basis of preparation of financial statements [text block]" } }, "en": { "role": { "documentation": "The disclosure of the basis used for the preparation of the financial statements." } } }, "auth_ref": [ "r220" ] }, "abvx_DisclosureOfBreakdownOfTradeAndOtherPayablesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "DisclosureOfBreakdownOfTradeAndOtherPayablesTableTextBlock", "presentation": [ "http://www.abivax.com/role/PayablesandothercurrentliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of breakdown of trade and other payables", "label": "Disclosure Of Breakdown Of Trade And Other Payables [Table Text Block]", "documentation": "Disclosure Of Breakdown Of Trade And Other Payables" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfCashAndCashEquivalentsExplanatory", "presentation": [ "http://www.abivax.com/role/Cashandcashequivalents" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Disclosure of cash and cash equivalents [text block]" } }, "en": { "role": { "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r220" ] }, "abvx_DisclosureOfCashAndCashEquivalentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "DisclosureOfCashAndCashEquivalentsLineItems", "presentation": [ "http://www.abivax.com/role/CashandcashequivalentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Cash And Cash Equivalents [Line Items]", "label": "Disclosure Of Cash And Cash Equivalents [Line Items]", "documentation": "Disclosure Of Cash And Cash Equivalents [Line Items]" } } }, "auth_ref": [] }, "abvx_DisclosureOfCashAndCashEquivalentsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "DisclosureOfCashAndCashEquivalentsTable", "presentation": [ "http://www.abivax.com/role/CashandcashequivalentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Cash And Cash Equivalents [Table]", "label": "Disclosure Of Cash And Cash Equivalents [Table]", "documentation": "Disclosure Of Cash And Cash Equivalents [Table]" } } }, "auth_ref": [] }, "abvx_DisclosureOfChangesInDerivativeFinancialInstrumentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "DisclosureOfChangesInDerivativeFinancialInstrumentsTableTextBlock", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of changes in derivative instruments", "label": "Disclosure Of Changes In Derivative Financial Instruments [Table Text Block]", "documentation": "Disclosure Of Changes In Derivative Financial Instruments" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalLineItems", "presentation": [ "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails", "http://www.abivax.com/role/ShareholdersequitySharecapitalissuedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of classes of share capital [line items]", "label": "Disclosure of classes of share capital [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalTable", "presentation": [ "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails", "http://www.abivax.com/role/ShareholdersequitySharecapitalissuedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of classes of share capital [table]", "label": "Disclosure of classes of share capital [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to classes of share capital." } } }, "auth_ref": [ "r25" ] }, "ifrs-full_DisclosureOfCommitmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfCommitmentsExplanatory", "presentation": [ "http://www.abivax.com/role/Offbalancesheetcommitmentsgiven" ], "lang": { "en-us": { "role": { "terseLabel": "Off-balance sheet commitments given", "label": "Disclosure of commitments [text block]" } }, "en": { "role": { "documentation": "The disclosure of commitments." } } }, "auth_ref": [ "r220" ] }, "abvx_DisclosureOfCompositionOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "DisclosureOfCompositionOfCashAndCashEquivalentsTableTextBlock", "presentation": [ "http://www.abivax.com/role/CashandcashequivalentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of composition of cash and cash equivalents", "label": "Disclosure Of Composition Of Cash And Cash Equivalents [Table Text Block]", "documentation": "Disclosure Of Composition Of Cash And Cash Equivalents" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfCreditRiskExposureLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfCreditRiskExposureLineItems", "presentation": [ "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of credit risk exposure [line items]", "label": "Disclosure of credit risk exposure [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfCreditRiskExposureTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfCreditRiskExposureTable", "presentation": [ "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of credit risk exposure [table]", "label": "Disclosure of credit risk exposure [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the credit risk exposure." } } }, "auth_ref": [ "r146" ] }, "ifrs-full_DisclosureOfDefinedBenefitPlansAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of defined benefit plans [abstract]", "label": "Disclosure of defined benefit plans [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about borrowings [line items]", "label": "Disclosure of detailed information about borrowings [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about borrowings [table]", "label": "Disclosure of detailed information about borrowings [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of borrowings." } } }, "auth_ref": [ "r250" ] }, "abvx_DisclosureOfDetailedInformationAboutFinanceIncomeCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "DisclosureOfDetailedInformationAboutFinanceIncomeCostTableTextBlock", "presentation": [ "http://www.abivax.com/role/FinancialgainlossTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of net financial income (loss)", "label": "Disclosure Of Detailed Information About Finance Income (Cost) [Table Text Block]", "documentation": "Disclosure Of Detailed Information About Finance Income (Cost)" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "presentation": [ "http://www.abivax.com/role/IntangibleassetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of reconciliation of intangible assets", "label": "Disclosure of detailed information about intangible assets [text block]" } }, "en": { "role": { "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r68" ] }, "abvx_DisclosureOfDetailedInformationAboutOtherReceivablesAndOtherAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "DisclosureOfDetailedInformationAboutOtherReceivablesAndOtherAssetsTableTextBlock", "presentation": [ "http://www.abivax.com/role/OtherreceivablesandotherassetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of other receivables and other assets", "label": "Disclosure Of Detailed Information About Other Receivables And Other Assets [Table Text Block]", "documentation": "Disclosure Of Detailed Information About Other Receivables And Other Assets" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Disclosure of reconciliation of property, plant and equipment", "label": "Disclosure of detailed information about property, plant and equipment [text block]" } }, "en": { "role": { "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r42" ] }, "abvx_DisclosureOfDetailedInformationOfOperatingIncomeExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "DisclosureOfDetailedInformationOfOperatingIncomeExplanatoryTableTextBlock", "presentation": [ "http://www.abivax.com/role/OperatingincomeTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of breakdown of operating income", "label": "Disclosure Of Detailed Information Of Operating Income Explanatory [Table Text Block]", "documentation": "Disclosure Of Detailed Information Of Operating Income Explanatory" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfEarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfEarningsPerShareExplanatory", "presentation": [ "http://www.abivax.com/role/Incomelosspershare" ], "lang": { "en-us": { "role": { "terseLabel": "Income (loss) per share", "label": "Disclosure of earnings per share [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r54" ] }, "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfEmployeeBenefitsExplanatory", "presentation": [ "http://www.abivax.com/role/Retirementbenefitobligations" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement benefit obligations", "label": "Disclosure of employee benefits [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for employee benefits." } } }, "auth_ref": [ "r45" ] }, "abvx_DisclosureOfEmployeeWorkforceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "DisclosureOfEmployeeWorkforceLineItems", "presentation": [ "http://www.abivax.com/role/EmployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Employee Workforce [Line Items]", "label": "Disclosure Of Employee Workforce [Line Items]", "documentation": "Disclosure Of Employee Workforce [Line Items]" } } }, "auth_ref": [] }, "abvx_DisclosureOfEmployeeWorkforceTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "DisclosureOfEmployeeWorkforceTable", "presentation": [ "http://www.abivax.com/role/EmployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Employee Workforce [Table]", "label": "Disclosure Of Employee Workforce [Table]", "documentation": "Disclosure Of Employee Workforce [Table]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfEntitysReportableSegmentsExplanatory", "presentation": [ "http://www.abivax.com/role/Segmentinformation" ], "lang": { "en-us": { "role": { "terseLabel": "Segment information", "label": "Disclosure of entity's operating segments [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for operating segments." } } }, "auth_ref": [ "r168" ] }, "ifrs-full_DisclosureOfExpensesByNatureExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfExpensesByNatureExplanatory", "presentation": [ "http://www.abivax.com/role/OperatingexpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of expenses by nature", "label": "Disclosure of expenses by nature [text block]" } }, "en": { "role": { "documentation": "The disclosure of expenses by nature. [Refer: Expenses, by nature]" } } }, "auth_ref": [ "r220" ] }, "abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]", "label": "Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]", "documentation": "Disclosure Of Fair Value Measurement Of Assets And Liabilities" } } }, "auth_ref": [] }, "abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Fair Value Measurement Of Assets And Liabilities [Table]", "label": "Disclosure Of Fair Value Measurement Of Assets And Liabilities [Table]", "documentation": "Disclosure Of Fair Value Measurement Of Assets And Liabilities" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfFairValueMeasurementOfAssetsExplanatory", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of carrying amounts and fair value of financial assets", "label": "Disclosure of fair value measurement of assets [text block]" } }, "en": { "role": { "documentation": "The disclosure of the fair value measurement of assets." } } }, "auth_ref": [ "r107" ] }, "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of carrying amounts and fair value of financial liabilities", "label": "Disclosure of fair value measurement of liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of the fair value measurement of liabilities." } } }, "auth_ref": [ "r107" ] }, "ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "presentation": [ "http://www.abivax.com/role/Financialassetsandliabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets and liabilities", "label": "Disclosure of fair value of financial instruments [text block]" } }, "en": { "role": { "documentation": "The disclosure of the fair value of financial instruments. [Refer: Classes of financial instruments [domain]; At fair value [member]]" } } }, "auth_ref": [ "r220" ] }, "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfFinanceIncomeExpenseExplanatory", "presentation": [ "http://www.abivax.com/role/Financialgainloss" ], "lang": { "en-us": { "role": { "terseLabel": "Financial gain (loss)", "label": "Disclosure of finance income (cost) [text block]" } }, "en": { "role": { "documentation": "The disclosure of finance income (cost). [Refer: Finance income (cost)]" } } }, "auth_ref": [ "r220" ] }, "ifrs-full_DisclosureOfFinancialAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfFinancialAssetsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of financial assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfFinancialAssetsExplanatory", "presentation": [ "http://www.abivax.com/role/OtherfinancialassetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of other financial assets", "label": "Disclosure of financial assets [text block]" } }, "en": { "role": { "documentation": "The disclosure of financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r152" ] }, "ifrs-full_DisclosureOfFinancialAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfFinancialAssetsLineItems", "presentation": [ "http://www.abivax.com/role/OtherfinancialassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of financial assets [line items]", "label": "Disclosure of financial assets [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfFinancialAssetsTable", "presentation": [ "http://www.abivax.com/role/OtherfinancialassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of financial assets [table]", "label": "Disclosure of financial assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to financial assets." } } }, "auth_ref": [ "r152" ] }, "abvx_DisclosureOfFinancialGainLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "DisclosureOfFinancialGainLossLineItems", "presentation": [ "http://www.abivax.com/role/FinancialgainlossNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Financial Gain (Loss) [Line Items]", "label": "Disclosure Of Financial Gain (Loss) [Line Items]", "documentation": "Disclosure Of Financial Gain (Loss) [Line Items]" } } }, "auth_ref": [] }, "abvx_DisclosureOfFinancialGainLossTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "DisclosureOfFinancialGainLossTable", "presentation": [ "http://www.abivax.com/role/FinancialgainlossNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Financial Gain (Loss) [Table]", "label": "Disclosure Of Financial Gain (Loss) [Table]", "documentation": "Disclosure Of Financial Gain (Loss) [Table]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsExplanatory", "presentation": [ "http://www.abivax.com/role/Financialliabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities", "label": "Disclosure of financial instruments [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for financial instruments." } } }, "auth_ref": [ "r159" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsLineItems", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about financial instruments [line items]", "label": "Disclosure of detailed information about financial instruments [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsTable", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about financial instruments [table]", "label": "Disclosure of detailed information about financial instruments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of financial instruments." } } }, "auth_ref": [ "r140", "r145", "r152" ] }, "ifrs-full_DisclosureOfFinancialLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfFinancialLiabilitiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of financial liabilities [abstract]", "label": "Disclosure of financial liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfFinancialLiabilitiesExplanatory", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of financial liabilities breakdown", "label": "Disclosure of financial liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of financial liabilities. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r152" ] }, "ifrs-full_DisclosureOfFinancialLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfFinancialLiabilitiesLineItems", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of financial liabilities [line items]", "label": "Disclosure of financial liabilities [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfFinancialLiabilitiesTable", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of financial liabilities [table]", "label": "Disclosure of financial liabilities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to financial liabilities." } } }, "auth_ref": [ "r152" ] }, "ifrs-full_DisclosureOfFinancialRiskManagementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfFinancialRiskManagementExplanatory", "presentation": [ "http://www.abivax.com/role/Managementandassessmentoffinancialrisks" ], "lang": { "en-us": { "role": { "terseLabel": "Management and assessment of financial risks", "label": "Disclosure of financial risk management [text block]" } }, "en": { "role": { "documentation": "The disclosure of the entity's financial risk management practices and policies." } } }, "auth_ref": [ "r220" ] }, "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "presentation": [ "http://www.abivax.com/role/TheGroup" ], "lang": { "en-us": { "role": { "terseLabel": "The Group", "label": "Disclosure of general information about financial statements [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for general information about financial statements." } } }, "auth_ref": [ "r10" ] }, "ifrs-full_DisclosureOfGeographicalAreasLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfGeographicalAreasLineItems", "presentation": [ "http://www.abivax.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of geographical areas [line items]", "label": "Disclosure of geographical areas [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfGeographicalAreasTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfGeographicalAreasTable", "presentation": [ "http://www.abivax.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of geographical areas [table]", "label": "Disclosure of geographical areas [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to geographical areas." } } }, "auth_ref": [ "r167" ] }, "ifrs-full_DisclosureOfGoodwillExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfGoodwillExplanatory", "presentation": [ "http://www.abivax.com/role/Goodwillandimpairmenttest" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and impairment test", "label": "Disclosure of goodwill [text block]" } }, "en": { "role": { "documentation": "The disclosure of goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r220" ] }, "abvx_DisclosureOfImpactOfTheUkraineRussiaHostilitiesOnTheGroupPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "DisclosureOfImpactOfTheUkraineRussiaHostilitiesOnTheGroupPolicyTextBlock", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Impact of the Ukraine/Russia Hostilities on the Group", "label": "Disclosure Of Impact Of The Ukraine/Russia Hostilities On The Group [Policy Text Block]", "documentation": "Disclosure Of Impact Of The Ukraine/Russia Hostilities On The Group" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfIncomeTaxExplanatory", "presentation": [ "http://www.abivax.com/role/Incometax" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax", "label": "Disclosure of income tax [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for income taxes." } } }, "auth_ref": [ "r38" ] }, "abvx_DisclosureOfIndirectMeasurementOfConvertibleLoansInstrumentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "DisclosureOfIndirectMeasurementOfConvertibleLoansInstrumentsTableTextBlock", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of main data and assumptions used for the measurement of convertible loan notes", "label": "Disclosure Of Indirect Measurement Of Convertible Loans Instruments [Table Text Block]", "documentation": "" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesTables", "http://www.abivax.com/role/SharebasedpaymentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of main data and assumptions used for the measurement of other equity instruments", "label": "Disclosure of indirect measurement of fair value of goods or services received, other equity instruments granted during period [text block]" } }, "en": { "role": { "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's other equity instruments (ie other than share options)." } } }, "auth_ref": [ "r131" ] }, "ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfInformationAboutEmployeesExplanatory", "presentation": [ "http://www.abivax.com/role/Employees" ], "lang": { "en-us": { "role": { "terseLabel": "Employees", "label": "Disclosure of information about employees [text block]" } }, "en": { "role": { "documentation": "The disclosure of information about employees." } } }, "auth_ref": [ "r220" ] }, "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsExplanatory", "presentation": [ "http://www.abivax.com/role/Intangibleassets" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Disclosure of intangible assets [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for intangible assets." } } }, "auth_ref": [ "r70" ] }, "ifrs-full_DisclosureOfIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsLineItems", "presentation": [ "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails", "http://www.abivax.com/role/IntangibleassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about intangible assets [line items]", "label": "Disclosure of detailed information about intangible assets [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsTable", "presentation": [ "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails", "http://www.abivax.com/role/IntangibleassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about intangible assets [table]", "label": "Disclosure of detailed information about intangible assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of intangible assets." } } }, "auth_ref": [ "r68" ] }, "abvx_DisclosureOfLeaseLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "DisclosureOfLeaseLiabilitiesLineItems", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Lease Liabilities [Line Items]", "label": "Disclosure Of Lease Liabilities [Line Items]", "documentation": "Disclosure Of Lease Liabilities [Line Items]" } } }, "auth_ref": [] }, "abvx_DisclosureOfLeaseLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "DisclosureOfLeaseLiabilitiesTable", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Lease Liabilities [Table]", "label": "Disclosure Of Lease Liabilities [Table]", "documentation": "Disclosure Of Lease Liabilities [Table]" } } }, "auth_ref": [] }, "abvx_DisclosureOfLeasesForLesseeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "DisclosureOfLeasesForLesseeTableTextBlock", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of variation in lease liabilities", "label": "Disclosure Of Leases For Lessee [Table Text Block]", "documentation": "Disclosure Of Leases For Lessee" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfMaterialAccountingPolicyInformationExplanatory", "presentation": [ "http://www.abivax.com/role/Accountingprinciples" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting principles", "label": "Disclosure of material accounting policy information [text block]" } }, "en": { "role": { "documentation": "The entire disclosure of material accounting policy information applied by the entity." } } }, "auth_ref": [ "r7" ] }, "ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of maturity analysis for derivative financial liabilities [line items]", "label": "Disclosure of maturity analysis for derivative financial liabilities [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of maturity analysis for derivative financial liabilities [table]", "label": "Disclosure of maturity analysis for derivative financial liabilities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the maturity analysis for derivative financial liabilities." } } }, "auth_ref": [ "r148" ] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems", "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of non-adjusting events after reporting period [line items]", "label": "Disclosure of non-adjusting events after reporting period [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable", "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of non-adjusting events after reporting period [table]", "label": "Disclosure of non-adjusting events after reporting period [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period." } } }, "auth_ref": [ "r34" ] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of reconciliation of other equity instruments", "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)." } } }, "auth_ref": [ "r249" ] }, "abvx_DisclosureOfOperatingIncomeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "DisclosureOfOperatingIncomeLineItems", "presentation": [ "http://www.abivax.com/role/OperatingincomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Operating Income [Line Items]", "label": "Disclosure Of Operating Income [Line Items]", "documentation": "Disclosure Of Operating Income [Line Items]" } } }, "auth_ref": [] }, "abvx_DisclosureOfOperatingIncomeTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "DisclosureOfOperatingIncomeTable", "presentation": [ "http://www.abivax.com/role/OperatingincomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Operating Income [Table]", "label": "Disclosure Of Operating Income [Table]", "documentation": "Disclosure Of Operating Income [Table]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOperatingSegmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfOperatingSegmentsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of operating segments [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfOtherAssetsExplanatory", "presentation": [ "http://www.abivax.com/role/Otherfinancialassets" ], "lang": { "en-us": { "role": { "terseLabel": "Other financial assets", "label": "Disclosure of other assets [text block]" } }, "en": { "role": { "documentation": "The disclosure of other assets. [Refer: Other assets]" } } }, "auth_ref": [ "r220" ] }, "ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfOtherOperatingExpenseExplanatory", "presentation": [ "http://www.abivax.com/role/Operatingexpenses" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Disclosure of other operating expense [text block]" } }, "en": { "role": { "documentation": "The disclosure of other operating expense. [Refer: Other operating income (expense)]" } } }, "auth_ref": [ "r220" ] }, "ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfOtherOperatingIncomeExplanatory", "presentation": [ "http://www.abivax.com/role/Operatingincome" ], "lang": { "en-us": { "role": { "terseLabel": "Operating income", "label": "Disclosure of other operating income [text block]" } }, "en": { "role": { "documentation": "The disclosure of other operating income. [Refer: Other operating income (expense)]" } } }, "auth_ref": [ "r220" ] }, "ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory", "presentation": [ "http://www.abivax.com/role/Offbalancesheetcommitmentsreceivedandcontingentassets" ], "lang": { "en-us": { "role": { "terseLabel": "Off-balance sheet commitments received and contingent assets", "label": "Disclosure of other provisions, contingent liabilities and contingent assets [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for other provisions, contingent liabilities and contingent assets." } } }, "auth_ref": [ "r61" ] }, "abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "DisclosureOfOtherReceivablesAndOtherAssetsLineItems", "presentation": [ "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Other Receivables And Other Assets [Line Items]", "label": "Disclosure Of Other Receivables And Other Assets [Line Items]", "documentation": "Disclosure Of Other Receivables And Other Assets [Line Items]" } } }, "auth_ref": [] }, "abvx_DisclosureOfOtherReceivablesAndOtherAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "DisclosureOfOtherReceivablesAndOtherAssetsTable", "presentation": [ "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Other Receivables And Other Assets [Table]", "label": "Disclosure Of Other Receivables And Other Assets [Table]", "documentation": "Disclosure Of Other Receivables And Other Assets [Table]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.abivax.com/role/Propertyplantandequipment" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "label": "Disclosure of property, plant and equipment [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for property, plant and equipment." } } }, "auth_ref": [ "r44" ] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about property, plant and equipment [line items]", "label": "Disclosure of detailed information about property, plant and equipment [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about property, plant and equipment [table]", "label": "Disclosure of detailed information about property, plant and equipment [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of property, plant and equipment." } } }, "auth_ref": [ "r42" ] }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of quantitative information about right-of-use assets [line items]", "label": "Disclosure of quantitative information about right-of-use assets [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of quantitative information about right-of-use assets [table]", "label": "Disclosure of quantitative information about right-of-use assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to right-of-use assets." } } }, "auth_ref": [ "r115" ] }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of reconciliation of liabilities arising from financing activities", "label": "Disclosure of reconciliation of liabilities arising from financing activities [text block]" } }, "en": { "role": { "documentation": "The disclosure of the reconciliation of liabilities arising from financing activities. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r190" ] }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of reconciliation of liabilities arising from financing activities [line items]", "label": "Disclosure of reconciliation of liabilities arising from financing activities [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of reconciliation of liabilities arising from financing activities [table]", "label": "Disclosure of reconciliation of liabilities arising from financing activities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the reconciliation of liabilities arising from financing activities." } } }, "auth_ref": [ "r190" ] }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfRelatedPartyExplanatory", "presentation": [ "http://www.abivax.com/role/Relatedparties" ], "lang": { "en-us": { "role": { "terseLabel": "Related parties", "label": "Disclosure of related party [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for related parties." } } }, "auth_ref": [ "r48" ] }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "presentation": [ "http://www.abivax.com/role/Shareholdersequity" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders\u2019 equity", "label": "Disclosure of share capital, reserves and other equity interest [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } } }, "auth_ref": [ "r26" ] }, "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory", "presentation": [ "http://www.abivax.com/role/Sharebasedpayments" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payments", "label": "Disclosure of share-based payment arrangements [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for share-based payment arrangements." } } }, "auth_ref": [ "r128" ] }, "abvx_DisclosureOfSignificantEventsForThePeriodReportedAndEventsAfterReportingPeriodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "DisclosureOfSignificantEventsForThePeriodReportedAndEventsAfterReportingPeriodTextBlock", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequentevents" ], "lang": { "en-us": { "role": { "terseLabel": "Significant events for the year ended December 31, 2024 and the three months ended March 31, 2025 and subsequent events", "label": "Disclosure Of Significant Events For The Period Reported And Events After Reporting Period [Text Block]", "documentation": "Disclosure Of Significant Events For The Period Reported And Events After Reporting Period" } } }, "auth_ref": [] }, "abvx_DisclosureOfTaxAndEmployeeRelatedPayablesExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "DisclosureOfTaxAndEmployeeRelatedPayablesExplanatoryTableTextBlock", "presentation": [ "http://www.abivax.com/role/PayablesandothercurrentliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of tax and employee-related payables", "label": "Disclosure Of Tax And Employee-Related Payables Explanatory [Table Text Block]", "documentation": "Disclosure Of Tax And Employee-Related Payables Explanatory" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureoffairvalueoftheBSAsatgrantdateusingtheBlackScholesmodelDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsForthethreemonthsendedMarch312025Details", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [line items]", "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureoffairvalueoftheBSAsatgrantdateusingtheBlackScholesmodelDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsForthethreemonthsendedMarch312025Details", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [table]", "label": "Disclosure of terms and conditions of share-based payment arrangement [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } } }, "auth_ref": [ "r130" ] }, "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfTradeAndOtherPayablesExplanatory", "presentation": [ "http://www.abivax.com/role/Payablesandothercurrentliabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Payables and other current liabilities", "label": "Disclosure of trade and other payables [text block]" } }, "en": { "role": { "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]" } } }, "auth_ref": [ "r220" ] }, "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfTradeAndOtherReceivablesExplanatory", "presentation": [ "http://www.abivax.com/role/Otherreceivablesandotherassets" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables and other assets", "label": "Disclosure of trade and other receivables [text block]" } }, "en": { "role": { "documentation": "The disclosure of trade and other receivables. [Refer: Trade and other receivables]" } } }, "auth_ref": [ "r220" ] }, "abvx_DisclosureOfWarrantsArrangementsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "DisclosureOfWarrantsArrangementsLineItems", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Warrants Arrangements [Line Items]", "label": "Disclosure Of Warrants Arrangements [Line Items]", "documentation": "Disclosure Of Warrants Arrangements" } } }, "auth_ref": [] }, "abvx_DisclosureOfWarrantsArrangementsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "DisclosureOfWarrantsArrangementsTable", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Warrants Arrangements [Table]", "label": "Disclosure Of Warrants Arrangements [Table]", "documentation": "Disclosure Of Warrants Arrangements" } } }, "auth_ref": [] }, "abvx_DiscountRateAppliedToLongTermAdvances": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "DiscountRateAppliedToLongTermAdvances", "presentation": [ "http://www.abivax.com/role/OtherfinancialassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disount rate applied to long-term advances", "label": "Discount Rate Applied To Long-Term Advances", "documentation": "Discount Rate Applied To Long-Term Advances" } } }, "auth_ref": [] }, "ifrs-full_DiscountRateMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DiscountRateMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate", "label": "Discount rate, measurement input [member]" } }, "en": { "role": { "documentation": "This member stands for a discount rate used as a measurement input used in valuation techniques based on a present value calculation." } } }, "auth_ref": [ "r246" ] }, "ifrs-full_DiscountedCashFlowMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DiscountedCashFlowMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discounted cash flow", "label": "Discounted cash flow [member]" } }, "en": { "role": { "documentation": "This member stands for a specific valuation technique consistent with the income approach that involves analysing future cash flow amounts through the application of present value techniques and inputs (for example, weighted average cost of capital, long-term revenue growth rate, long-term pre-tax operating margin, discount for lack of marketability, control premium). [Refer: Income approach [member]; Weighted average [member]]" } } }, "auth_ref": [ "r196", "r202" ] }, "ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisposalsIntangibleAssetsOtherThanGoodwill", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Disposal", "label": "Disposals, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The decrease in intangible assets other than goodwill resulting from disposals. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r64" ] }, "ifrs-full_DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Disposal", "label": "Disposals, property, plant and equipment including right-of-use assets" } }, "en": { "role": { "documentation": "The decrease in property, plant and equipment including right-of-use assets resulting from disposals. [Refer: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r233" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "abvx_EarlyRedemptionAmountMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "EarlyRedemptionAmountMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Early redemption amount (put event)", "label": "Early Redemption Amount, Measurement Input [Member]", "documentation": "Early Redemption Amount, Measurement Input" } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFLOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Loss per share (\u20ac/share)", "label": "Earnings per share [abstract]" } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "EarningsPerShareExplanatory", "presentation": [ "http://www.abivax.com/role/IncomelosspershareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of earnings per share", "label": "Earnings per share [text block]" } }, "en": { "role": { "documentation": "The disclosure of earnings per share." } } }, "auth_ref": [ "r51" ] }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abivax.com/role/CashandcashequivalentsNarrativeDetails", "http://www.abivax.com/role/FinancialgainlossNarrativeDetails", "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of movements in exchange rates on cash held", "verboseLabel": "Effect of exchange rate changes on cash and cash equivalents", "label": "Effect of exchange rate changes on cash and cash equivalents" } }, "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r80", "r81" ] }, "ifrs-full_EmployeeBenefitsExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "EmployeeBenefitsExpense", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails", "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails", "http://www.abivax.com/role/OperatingexpensesDisclosureofsalesandmarketingexpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Personnel costs", "label": "Employee benefits expense" } }, "en": { "role": { "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment." } } }, "auth_ref": [ "r0", "r33", "r172" ] }, "abvx_EmployeesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "EmployeesAbstract", "lang": { "en-us": { "role": { "label": "Employees [Abstract]", "documentation": "Employees [Abstract]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Country", "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r219" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r219" ] }, "ifrs-full_Equity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "Equity", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails", "http://www.abivax.com/role/ShareholdersequitySharecapitalissuedDetails", "http://www.abivax.com/role/TheGroupDetails", "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "totalLabel": "Total shareholders\u2019 equity", "periodStartLabel": "Equity at beginning of period", "periodEndLabel": "Equity at end of period", "terseLabel": "Equity", "label": "Equity" } }, "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } } }, "auth_ref": [ "r15", "r22", "r89", "r91", "r102", "r103", "r105" ] }, "ifrs-full_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "EquityAbstract", "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders\u2019 equity", "label": "Equity [abstract]" } } }, "auth_ref": [] }, "ifrs-full_EquityAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "EquityAndLiabilities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY", "label": "Equity and liabilities" } }, "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } } }, "auth_ref": [ "r15" ] }, "ifrs-full_EquityAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "EquityAndLiabilitiesAbstract", "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY", "label": "Equity and liabilities [abstract]" } } }, "auth_ref": [] }, "abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted": { "xbrltype": "perShareItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "EquityInstrumentFairValueOtherEquityInstrumentsGranted", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureoffairvalueoftheBSAsatgrantdateusingtheBlackScholesmodelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "FAIR VALUE OF THE AGA (in euro per share)", "label": "Equity Instrument Fair Value, Other Equity Instruments Granted", "documentation": "Equity Instrument Fair Value, Other Equity Instruments Granted" } } }, "auth_ref": [] }, "abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted": { "xbrltype": "perShareItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "EquityInstrumentPriceOtherEquityInstrumentsGranted", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureoffairvalueoftheBSAsatgrantdateusingtheBlackScholesmodelDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "SUBSCRIPTION PRICE (in euro per share)", "label": "Equity Instrument Price, Other Equity Instruments Granted", "documentation": "Equity Instrument Price, Other Equity Instruments Granted" } } }, "auth_ref": [] }, "abvx_EquityInstrumentStrikePriceOtherEquityInstrumentsGranted": { "xbrltype": "perShareItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "EquityInstrumentStrikePriceOtherEquityInstrumentsGranted", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureoffairvalueoftheBSAsatgrantdateusingtheBlackScholesmodelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "STRIKE PRICE PER SHARE (in euro per share)", "label": "Equity Instrument Strike Price, Other Equity Instruments Granted", "documentation": "Equity Instrument Strike Price, Other Equity Instruments Granted" } } }, "auth_ref": [] }, "abvx_ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember", "presentation": [ "http://www.abivax.com/role/IntangibleassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exclusive licensing agreement with CNRS, University of Montpellier and Institut Curie", "label": "Exclusive Licensing Agreement With CNRS, University Of Montpellier And Institut Curie [Member]", "documentation": "Exclusive Licensing Agreement With CNRS, University Of Montpellier And Institut Curie" } } }, "auth_ref": [] }, "abvx_ExercisePricePerShareMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "ExercisePricePerShareMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price per share (in euro per share)", "label": "Exercise Price Per Share, Measurement Input [Member]", "documentation": "Exercise Price Per Share, Measurement Input" } } }, "auth_ref": [] }, "abvx_ExpectedDividendMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "ExpectedDividendMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividend", "label": "Expected Dividend, Measurement Input [Member]", "documentation": "Expected Dividend, Measurement Input" } } }, "auth_ref": [] }, "abvx_ExpectedMaturityOtherEquityInstrumentsGranted": { "xbrltype": "durationItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "ExpectedMaturityOtherEquityInstrumentsGranted", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureoffairvalueoftheBSAsatgrantdateusingtheBlackScholesmodelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "EXPECTED MATURITY", "label": "Expected Maturity, Other Equity Instruments Granted", "documentation": "Expected Maturity, Other Equity Instruments Granted" } } }, "auth_ref": [] }, "abvx_ExpectedProceedsFromShareIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "ExpectedProceedsFromShareIssuance", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Expected proceeds from share issuance", "label": "Expected Proceeds From Share Issuance", "documentation": "Expected Proceeds From Share Issuance" } } }, "auth_ref": [] }, "abvx_ExpectedProceedsFromShareIssuanceShelfRegistration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "ExpectedProceedsFromShareIssuanceShelfRegistration", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Expected proceeds from share issuance, shelf registration", "label": "Expected Proceeds From Share Issuance, Shelf Registration", "documentation": "Expected Proceeds From Share Issuance, Shelf Registration" } } }, "auth_ref": [] }, "abvx_ExpectedVolatilityOtherEquityInstrumentsGranted": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "ExpectedVolatilityOtherEquityInstrumentsGranted", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureoffairvalueoftheBSAsatgrantdateusingtheBlackScholesmodelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "VOLATILITY", "label": "Expected Volatility, Other Equity Instruments Granted", "documentation": "Expected Volatility, Other Equity Instruments Granted" } } }, "auth_ref": [] }, "ifrs-full_ExpenseByNatureAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ExpenseByNatureAbstract", "lang": { "en-us": { "role": { "label": "Expenses by nature [abstract]" } } }, "auth_ref": [] }, "abvx_ExpenseFromEquitySettledShareBasedPaymentTransactionsSocialTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "ExpenseFromEquitySettledShareBasedPaymentTransactionsSocialTaxes", "crdr": "debit", "calculation": { "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails": { "parentTag": "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Social taxes related to AGAs", "label": "Expense From Equity-Settled Share-Based Payment Transactions, Social Taxes", "documentation": "Expense From Equity-Settled Share-Based Payment Transactions, Social Taxes" } } }, "auth_ref": [] }, "ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "crdr": "debit", "calculation": { "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails": { "parentTag": "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Share-based compensation expense", "label": "Expense from equity-settled share-based payment transactions" } }, "en": { "role": { "documentation": "The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions]" } } }, "auth_ref": [ "r133" ] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "crdr": "debit", "calculation": { "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Expense from share-based payment transactions" } }, "en": { "role": { "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets." } } }, "auth_ref": [ "r133" ] }, "abvx_ExpenseOnLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "ExpenseOnLeaseLiabilities", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expense on lease liabilities", "label": "Expense On Lease Liabilities", "documentation": "Expense On Lease Liabilities" } } }, "auth_ref": [] }, "abvx_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expense relating to short-term leases", "label": "Expense Relating To Short-Term Leases And Low Value Assets For Which Recognition Exemption Has Been Used", "documentation": "Expense Relating To Short-Term Leases And Low Value Assets For Which Recognition Exemption Has Been Used" } } }, "auth_ref": [] }, "abvx_ExpiryScenarioPeriodOtherEquityInstrumentsGranted": { "xbrltype": "durationItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "ExpiryScenarioPeriodOtherEquityInstrumentsGranted", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expiry scenario period, other equity instruments granted", "label": "Expiry Scenario Period, Other Equity Instruments Granted", "documentation": "Expiry Scenario Period, Other Equity Instruments Granted" } } }, "auth_ref": [] }, "abvx_ExpiryScenarioProbablityMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "ExpiryScenarioProbablityMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "7-year expiry scenario probability", "label": "Expiry Scenario Probablity, Measurement Input [Member]", "documentation": "Expiry Scenario Probablity, Measurement Input" } } }, "auth_ref": [] }, "ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of breakdown of the compensation expenses", "label": "Explanation of effect of share-based payments on entity's profit or loss [text block]" } }, "en": { "role": { "documentation": "The explanation that enables users of financial statements to understand the effect of share-based payment transactions on the entity's profit (loss)." } } }, "auth_ref": [ "r132" ] }, "country_FR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "FR", "presentation": [ "http://www.abivax.com/role/EmployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "France", "label": "FRANCE" } } }, "auth_ref": [] }, "abvx_FairValueMeasurementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "FairValueMeasurementAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Measurement [Abstract]", "documentation": "Fair Value Measurement [Abstract]" } } }, "auth_ref": [] }, "abvx_FinalRedemptionFairValueOfMRIMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "FinalRedemptionFairValueOfMRIMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total fair value of MRI, final redemption", "label": "Final Redemption, Fair Value Of MRI , Measurement Input [Member]", "documentation": "Final Redemption, Fair Value Of MRI , Measurement Input" } } }, "auth_ref": [] }, "abvx_FinalRedemptionProbabilityWeightedFairValueWithMRIMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "FinalRedemptionProbabilityWeightedFairValueWithMRIMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Final redemption, probability-weighted fair value with MRI", "label": "Final Redemption, Probability-Weighted Fair Value With MRI , Measurement Input [Member]", "documentation": "Final Redemption, Probability-Weighted Fair Value With MRI , Measurement Input" } } }, "auth_ref": [] }, "abvx_FinalRedemptionProbabilityWeightedFairValueWithoutMRIMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "FinalRedemptionProbabilityWeightedFairValueWithoutMRIMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Final redemption, probability-weighted fair value without MRI", "label": "Final Redemption, Probability-Weighted Fair Value Without MRI , Measurement Input [Member]", "documentation": "Final Redemption, Probability-Weighted Fair Value Without MRI , Measurement Input" } } }, "auth_ref": [] }, "abvx_FinalRedemptionProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "FinalRedemptionProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Probability-weighted present value of shortfall payment, final redemption", "label": "Final Redemption, Probability-Weighted Present Value Of Shortfall Payment, Measurement Input [Member]", "documentation": "Final Redemption,Probability-Weighted Present Value Of Shortfall Payment, Measurement Input" } } }, "auth_ref": [] }, "abvx_FinalRedemptionScenarioProbabilityMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "FinalRedemptionScenarioProbabilityMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Final redemption scenario probability", "label": "Final Redemption Scenario Probability, Measurement Input [Member]", "documentation": "Final Redemption Scenario Probability, Measurement Input" } } }, "auth_ref": [] }, "ifrs-full_FinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "FinanceCosts", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFLOSS": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": -1.0, "order": 1.0 }, "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails", "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFLOSS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Financial expenses", "negatedTotalLabel": "Financial expenses", "label": "Finance costs" } }, "en": { "role": { "documentation": "The amount of costs associated with financing activities of the entity." } } }, "auth_ref": [ "r30" ] }, "ifrs-full_FinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "FinanceIncome", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFLOSS": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0, "order": 2.0 }, "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails", "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFLOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Financial income", "totalLabel": "Financial income", "label": "Finance income" } }, "en": { "role": { "documentation": "The amount of income associated with interest and other financing activities of the entity." } } }, "auth_ref": [ "r230" ] }, "ifrs-full_FinanceIncomeCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "FinanceIncomeCost", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFLOSS": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails", "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFLOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Financial gain (loss)", "label": "Finance income (cost)" } }, "en": { "role": { "documentation": "The amount of income or cost associated with interest and other financing activities of the entity." } } }, "auth_ref": [ "r230" ] }, "ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "FinancialAssetsAtAmortisedCostCategoryMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS AT AMORTIZED COST", "label": "Financial assets at amortised cost, category [member]" } }, "en": { "role": { "documentation": "This member stands for the financial assets at amortised cost category. [Refer: Financial assets at amortised cost]" } } }, "auth_ref": [ "r155" ] }, "ifrs-full_FinancialAssetsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "FinancialAssetsAtFairValue", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets, at fair value", "label": "Financial assets, at fair value" } }, "en": { "role": { "documentation": "The fair value of financial assets. [Refer: At fair value [member]; Financial assets]" } } }, "auth_ref": [ "r139" ] }, "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS AT FAIR VALUE THROUGH PROFIT\u00a0AND LOSS", "label": "Financial assets at fair value through profit or loss, category [member]" } }, "en": { "role": { "documentation": "This member stands for the financial assets at fair value through profit or loss category. [Refer: Financial assets at fair value through profit or loss]" } } }, "auth_ref": [ "r153" ] }, "abvx_FinancialIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "FinancialIncomeLossAbstract", "lang": { "en-us": { "role": { "label": "Financial Income (Loss) [Abstract]", "documentation": "Financial Income (Loss)" } } }, "auth_ref": [] }, "ifrs-full_FinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "FinancialLiabilities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total financial liabilities", "label": "Financial liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r139" ] }, "ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "FinancialLiabilitiesAtAmortisedCostCategoryMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AT\u00a0AMORTIZED COST", "label": "Financial liabilities at amortised cost, category [member]" } }, "en": { "role": { "documentation": "This member stands for the financial liabilities at amortised cost category. [Refer: Financial liabilities at amortised cost]" } } }, "auth_ref": [ "r156" ] }, "ifrs-full_FinancialLiabilitiesAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "FinancialLiabilitiesAtFairValue", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities, at fair value", "label": "Financial liabilities, at fair value" } }, "en": { "role": { "documentation": "The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]" } } }, "auth_ref": [ "r139" ] }, "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AT FAIR VALUE THROUGH PROFIT\u00a0AND LOSS", "label": "Financial liabilities at fair value through profit or loss, category [member]" } }, "en": { "role": { "documentation": "This member stands for the financial liabilities at fair value through profit or loss category. [Refer: Financial liabilities at fair value through profit or loss]" } } }, "auth_ref": [ "r154" ] }, "abvx_FinancialLiabilitiesUndiscountedCashFlows": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "FinancialLiabilitiesUndiscountedCashFlows", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Financial liabilities, undiscounted cash flows", "label": "Financial Liabilities, Undiscounted Cash Flows", "documentation": "Financial Liabilities, Undiscounted Cash Flows" } } }, "auth_ref": [] }, "abvx_FinancialRiskManagementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "FinancialRiskManagementAbstract", "lang": { "en-us": { "role": { "label": "Financial Risk Management [Abstract]", "documentation": "Financial Risk Management [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_ForeignExchangeGain": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ForeignExchangeGain", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange gains", "label": "Foreign exchange gain" } }, "en": { "role": { "documentation": "The gross gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } } }, "auth_ref": [ "r9", "r46" ] }, "ifrs-full_ForeignExchangeLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ForeignExchangeLoss", "crdr": "debit", "calculation": { "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Foreign exchange losses", "label": "Foreign exchange loss" } }, "en": { "role": { "documentation": "The gross loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } } }, "auth_ref": [ "r9", "r46" ] }, "abvx_FoundersShareSubscriptionWarrantsBCEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "FoundersShareSubscriptionWarrantsBCEMember", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total BCEs", "verboseLabel": "BCEs", "label": "Founders\u2019 Share Subscription Warrants (BCE) [Member]", "documentation": "Founders\u2019 Share Subscription Warrants (BCE)" } } }, "auth_ref": [] }, "abvx_FreeSharesAGAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "FreeSharesAGAMember", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "AGAs", "terseLabel": "Total AGAs", "label": "Free Shares (AGA) [Member]", "documentation": "Free Shares (AGA)" } } }, "auth_ref": [] }, "abvx_FurnitureAndComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "FurnitureAndComputerEquipmentMember", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "FURNITURE AND COMPUTER EQUIPMENT", "label": "Furniture And Computer Equipment [Member]", "documentation": "Furniture And Computer Equipment" } } }, "auth_ref": [] }, "abvx_GainsArisingFromRecognitionOfFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "GainsArisingFromRecognitionOfFinancialLiabilities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Day-one gain on recognition of financial liabilities", "label": "Gains Arising From Recognition Of Financial Liabilities", "documentation": "Gains Arising From Recognition Of Financial Liabilities" } } }, "auth_ref": [] }, "ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease/(increase) in other liabilities at fair value through profit and loss", "label": "Gains (losses) on financial liabilities at fair value through profit or loss" } }, "en": { "role": { "documentation": "The gains (losses) on financial liabilities at fair value through profit or loss. [Refer: Financial liabilities at fair value through profit or loss]" } } }, "auth_ref": [ "r136" ] }, "ifrs-full_GainsOnChangeInFairValueOfDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "GainsOnChangeInFairValueOfDerivatives", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Decrease in fair value", "terseLabel": "Decrease/(increase) in derivatives fair value", "label": "Gains on change in fair value of derivatives" } }, "en": { "role": { "documentation": "The gains resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]" } } }, "auth_ref": [ "r230" ] }, "ifrs-full_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFLOSS": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFLOSS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "General and administrative", "label": "General and administrative expense" } }, "en": { "role": { "documentation": "The amount of expense relating to general and administrative activities of the entity." } } }, "auth_ref": [ "r224" ] }, "abvx_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.abivax.com/role/OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails", "http://www.abivax.com/role/OperatingexpensesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative expense", "label": "General And Administrative Expense [Member]", "documentation": "General And Administrative Expense" } } }, "auth_ref": [] }, "ifrs-full_GeographicalAreasAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "GeographicalAreasAxis", "presentation": [ "http://www.abivax.com/role/EmployeesDetails", "http://www.abivax.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical areas [axis]", "label": "Geographical areas [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r167", "r180", "r203", "r207" ] }, "ifrs-full_GeographicalAreasDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "GeographicalAreasDomain", "presentation": [ "http://www.abivax.com/role/EmployeesDetails", "http://www.abivax.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical areas [domain]", "label": "Geographical areas [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used." } } }, "auth_ref": [ "r167", "r180", "r203", "r207" ] }, "ifrs-full_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/GoodwillandimpairmenttestDetails", "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill" } }, "en": { "role": { "documentation": "The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Total for all business combinations [member]]" } } }, "auth_ref": [ "r11", "r57", "r59", "r134" ] }, "ifrs-full_GrossCarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "GrossCarryingAmountMember", "presentation": [ "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails", "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "GROSS VALUES", "label": "Gross carrying amount [member]" } }, "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]" } } }, "auth_ref": [ "r39", "r62", "r73", "r76", "r134", "r144", "r146", "r208" ] }, "ifrs-full_GrossLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "GrossLeaseLiabilities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": "abvx_FinancialLiabilitiesUndiscountedCashFlows", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross lease liabilities", "label": "Gross lease liabilities" } }, "en": { "role": { "documentation": "The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r116", "r211" ] }, "abvx_GrossProceedsFromNonConvertibleLoansNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "GrossProceedsFromNonConvertibleLoansNotes", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Proceeds From Non-Convertible Loans Notes", "label": "Gross Proceeds From Non-Convertible Loans Notes", "documentation": "Gross Proceeds From Non-Convertible Loans Notes" } } }, "auth_ref": [] }, "abvx_HeightsConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "HeightsConvertibleNotesMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Heights convertible notes", "label": "Heights Convertible Notes [Member]", "documentation": "Heights Convertible Notes" } } }, "auth_ref": [] }, "abvx_HeightsConvertibleNotesTrancheAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "HeightsConvertibleNotesTrancheAMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Heights convertible notes, tranche A", "label": "Heights Convertible Notes, Tranche A [Member]", "documentation": "Heights Convertible Notes, Tranche A" } } }, "auth_ref": [] }, "ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "HistoricalVolatilityForSharesMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Volatility", "label": "Historical volatility for shares, measurement input [member]" } }, "en": { "role": { "documentation": "This member stands for the historical volatility for shares used as a measurement input." } } }, "auth_ref": [ "r199" ] }, "ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill", "presentation": [ "http://www.abivax.com/role/IntangibleassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment loss recognised in profit or loss, other intangible assets", "label": "Impairment loss recognised in profit or loss, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The amount of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r65" ] }, "abvx_IncomeFromResearchTaxCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "IncomeFromResearchTaxCredit", "crdr": "credit", "calculation": { "http://www.abivax.com/role/OperatingincomeDisclosureofbreakdownofoperatingincomeDetails": { "parentTag": "ifrs-full_OtherIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/OperatingincomeDisclosureofbreakdownofoperatingincomeDetails", "http://www.abivax.com/role/OperatingincomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research tax credit (\"CIR\")", "label": "Income From Research Tax Credit", "documentation": "Income From Research Tax Credit" } } }, "auth_ref": [] }, "ifrs-full_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Profit or loss [abstract]" } } }, "auth_ref": [] }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncomeTaxExpenseContinuingOperations", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFLOSS": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFLOSS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Income tax", "label": "Tax expense (income)" } }, "en": { "role": { "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]" } } }, "auth_ref": [ "r31", "r35", "r36", "r37", "r50", "r101", "r161" ] }, "ifrs-full_IncomeTaxesPaidRefundAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncomeTaxesPaidRefundAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income taxes paid (refund) [abstract]", "label": "Income taxes paid (refund) [abstract]" } } }, "auth_ref": [] }, "abvx_IncreaseDecreaseFromFreeSharesIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "IncreaseDecreaseFromFreeSharesIssued", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issue of free shares", "label": "Increase (Decrease) From Free Shares Issued", "documentation": "Increase (Decrease) From Free Shares Issued" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Decrease in cash and cash equivalents", "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r87" ] }, "abvx_IncreaseDecreaseInEmployeeBenefitsExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "IncreaseDecreaseInEmployeeBenefitsExpenses", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/OperatingexpensesNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Decrease in employee benefits expenses", "label": "Increase (Decrease) In Employee Benefits Expenses", "documentation": "Increase (Decrease) In Employee Benefits Expenses" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in financial liabilities at fair value due to reasonably possible decrease in unobservable input", "label": "Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, liabilities" } }, "en": { "role": { "documentation": "The amount of increase (decrease) in the fair value measurement of liabilities due to a reasonably possible decrease in an unobservable input." } } }, "auth_ref": [ "r106" ] }, "ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease in financial assets at fair value", "terseLabel": "Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets", "label": "Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets" } }, "en": { "role": { "documentation": "The amount of increase (decrease) in the fair value measurement of assets due to a reasonably possible increase in an unobservable input." } } }, "auth_ref": [ "r106" ] }, "ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease in financial liabilities at fair value", "terseLabel": "Increase (decrease) in financial liabilities at fair value due to reasonably possible increase in unobservable input", "label": "Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, liabilities" } }, "en": { "role": { "documentation": "The amount of increase (decrease) in the fair value measurement of liabilities due to a reasonably possible increase in an unobservable input." } } }, "auth_ref": [ "r106" ] }, "abvx_IncreaseDecreaseInOperatingExpensesCDProgram": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "IncreaseDecreaseInOperatingExpensesCDProgram", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/OperatingexpensesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in operating expenses, CD program", "label": "Increase (Decrease) In Operating Expenses, CD Program", "documentation": "Increase (Decrease) In Operating Expenses, CD Program" } } }, "auth_ref": [] }, "abvx_IncreaseDecreaseInOperatingExpensesTransversalActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "IncreaseDecreaseInOperatingExpensesTransversalActivities", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/OperatingexpensesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in operating expenses, transversal activities", "label": "Increase (Decrease) In Operating Expenses, Transversal Activities", "documentation": "Increase (Decrease) In Operating Expenses, Transversal Activities" } } }, "auth_ref": [] }, "abvx_IncreaseDecreaseInOperatingExpensesUCClinicalProgram": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "IncreaseDecreaseInOperatingExpensesUCClinicalProgram", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/OperatingexpensesNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Decrease in operating expenses, UC clinical program", "label": "Increase (Decrease) In Operating Expenses, UC Clinical Program", "documentation": "Increase (Decrease) In Operating Expenses, UC Clinical Program" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncreaseDecreaseInWorkingCapital", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Changes in working capital requirements", "label": "Increase (decrease) in working capital" } }, "en": { "role": { "documentation": "The increase (decrease) in working capital." } } }, "auth_ref": [ "r244" ] }, "ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughAppropriationOfRetainedEarnings", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Appropriation of prior period net loss", "label": "Increase (decrease) through appropriation of retained earnings, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the appropriation of retained earnings. [Refer: Retained earnings]" } } }, "auth_ref": [ "r222" ] }, "ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash changes: other fair value remeasurement", "label": "Increase (decrease) through changes in fair values, liabilities arising from financing activities" } }, "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from changes in fair values. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r84" ] }, "abvx_IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash changes: classification of embedded derivatives as separate derivative financial instruments", "label": "Increase (Decrease) Through Classification of Embedded Derivatives as Separate Financial Instruments, Liabilities Arising From Financing Activities", "documentation": "Increase (Decrease) Through Classification of Embedded Derivatives as Separate Financial Instruments, Liabilities Arising From Financing Activities" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non cash changes : Effect of the change in foreign currency exhange rates", "label": "Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities" } }, "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from the effect of changes in foreign exchange rates. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r83" ] }, "abvx_IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash changes: (gain)/loss on recognition or derecognition", "label": "Increase (Decrease) Through Gain (Loss) On Recognition/Derecognition, Liabilities Arising From Financing Activities", "documentation": "Increase (Decrease) Through Gain (Loss) On Recognition/Derecognition, Liabilities Arising From Financing Activities" } } }, "auth_ref": [] }, "abvx_IncreaseDecreaseThroughIssuanceOfWarrantsEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "IncreaseDecreaseThroughIssuanceOfWarrantsEquity", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issue of share warrants", "label": "Increase (Decrease) Through Issuance of Warrants, Equity", "documentation": "Increase (Decrease) Through Issuance of Warrants, Equity" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of the change in foreign currency exhange rates", "label": "Increase (decrease) through net exchange differences, property, plant and equipment including right-of-use assets" } }, "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment including right-of-use assets resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r233" ] }, "ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash changes: interest expense and other", "label": "Increase (decrease) through other changes, liabilities arising from financing activities" } }, "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r85" ] }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Shares based compensation expense", "label": "Increase (decrease) through share-based payment transactions, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } } }, "auth_ref": [ "r4" ] }, "ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughTreasuryShareTransactions", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Transactions on treasury shares", "label": "Increase (decrease) through treasury share transactions, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]" } } }, "auth_ref": [ "r5" ] }, "abvx_IncreaseInLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "IncreaseInLeaseLiabilities", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofvariationinleaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase", "label": "Increase In Lease Liabilities", "documentation": "Increase In Lease Liabilities" } } }, "auth_ref": [] }, "abvx_IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds", "label": "Increase Through Proceeds, Liabilities Arising From Financing Activities", "documentation": "Increase Through Proceeds, Liabilities Arising From Financing Activities" } } }, "auth_ref": [] }, "ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis", "presentation": [ "http://www.abivax.com/role/IntangibleassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash-generating units [axis]", "label": "Cash-generating units [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r58" ] }, "ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain", "presentation": [ "http://www.abivax.com/role/IntangibleassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash-generating units [domain]", "label": "Cash-generating units [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Cash-generating units' axis if no other member is used." } } }, "auth_ref": [ "r58", "r60" ] }, "abvx_InitialPriceLimitMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "InitialPriceLimitMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial price limit (in euro per share)", "label": "Initial Price Limit, Measurement Input [Member]", "documentation": "Initial Price Limit, Measurement Input" } } }, "auth_ref": [] }, "ifrs-full_IntangibleAssetsAndGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IntangibleAssetsAndGoodwillAbstract", "lang": { "en-us": { "role": { "label": "Intangible assets and goodwill [abstract]" } } }, "auth_ref": [] }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails", "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "periodStartLabel": "Intangible assets other than goodwill at beginning of period", "periodEndLabel": "Intangible assets other than goodwill at end of period", "label": "Intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r11", "r67" ] }, "ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwillAbstract", "lang": { "en-us": { "role": { "label": "Intangible assets other than goodwill [abstract]" } } }, "auth_ref": [] }, "abvx_IntellectualPropertyFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "IntellectualPropertyFees", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intellectual property fees", "label": "Intellectual Property Fees", "documentation": "Intellectual Property Fees" } } }, "auth_ref": [] }, "ifrs-full_InterestExpenseOnBonds": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "InterestExpenseOnBonds", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest on bond loans", "label": "Interest expense on bonds" } }, "en": { "role": { "documentation": "The amount of interest expense on bonds issued. [Refer: Interest expense; Bonds issued]" } } }, "auth_ref": [ "r224" ] }, "abvx_InterestExpenseOnBondsIncludingAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "InterestExpenseOnBondsIncludingAdjustments", "crdr": "debit", "calculation": { "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest on bond loans", "label": "Interest Expense On Bonds, Including Adjustments", "documentation": "Interest Expense On Bonds, Including Adjustments" } } }, "auth_ref": [] }, "ifrs-full_InterestExpenseOnBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "InterestExpenseOnBorrowings", "crdr": "debit", "calculation": { "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest on conditional advances", "label": "Interest expense on borrowings" } }, "en": { "role": { "documentation": "The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]" } } }, "auth_ref": [ "r224" ] }, "ifrs-full_InterestExpenseOnDebtInstrumentsIssued": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "InterestExpenseOnDebtInstrumentsIssued", "crdr": "debit", "calculation": { "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest on convertible loan notes", "label": "Interest expense on debt instruments issued" } }, "en": { "role": { "documentation": "The amount of interest expense on debt instruments issued. [Refer: Interest expense; Debt instruments issued]" } } }, "auth_ref": [ "r224" ] }, "ifrs-full_InterestExpenseOnLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "InterestExpenseOnLeaseLiabilities", "crdr": "debit", "calculation": { "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails", "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense on lease liabilities", "negatedTerseLabel": "Interest on lease liabilities", "label": "Interest expense on lease liabilities" } }, "en": { "role": { "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r113" ] }, "abvx_InterestExpenseOnRoyaltyCertificates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "InterestExpenseOnRoyaltyCertificates", "crdr": "debit", "calculation": { "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest on royalty certificates", "label": "Interest Expense On Royalty Certificates", "documentation": "Interest Expense On Royalty Certificates" } } }, "auth_ref": [] }, "ifrs-full_InterestPaidClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "InterestPaidClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest paid", "label": "Interest paid, classified as financing activities" } }, "en": { "role": { "documentation": "The cash outflow for interest paid, classified as financing activities." } } }, "auth_ref": [ "r82" ] }, "ifrs-full_InterestRateMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "InterestRateMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate", "label": "Interest rate, measurement input [member]" } }, "en": { "role": { "documentation": "This member stands for an interest rate used as a measurement input." } } }, "auth_ref": [ "r198" ] }, "ifrs-full_InterestReceivedClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "InterestReceivedClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Interest received", "label": "Interest received, classified as investing activities" } }, "en": { "role": { "documentation": "The cash inflow from interest received, classified as investing activities." } } }, "auth_ref": [ "r82" ] }, "abvx_IssuanceOfDerivativeInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "IssuanceOfDerivativeInstruments", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance", "label": "Issuance Of Derivative Instruments", "documentation": "Issuance Of Derivative Instruments" } } }, "auth_ref": [] }, "ifrs-full_IssuedCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IssuedCapital", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital", "label": "Issued capital" } }, "en": { "role": { "documentation": "The nominal value of capital issued." } } }, "auth_ref": [ "r176" ] }, "ifrs-full_IssuedCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IssuedCapitalMember", "presentation": [ "http://www.abivax.com/role/ShareholdersequitySharecapitalissuedDetails", "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "SHARE CAPITAL", "verboseLabel": "Issued capital", "label": "Issued capital [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } } }, "auth_ref": [ "r6" ] }, "abvx_Kreos12BondLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "Kreos12BondLoansMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos 1 & 2 bond loans", "label": "Kreos 1 & 2 Bond Loans [Member]", "documentation": "Kreos 1 & 2 Bond Loans" } } }, "auth_ref": [] }, "abvx_KreosABAndCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "KreosABAndCMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos A-B and C", "label": "Kreos A-B And C [Member]", "documentation": "Kreos A-B And C" } } }, "auth_ref": [] }, "abvx_KreosABBSAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "KreosABBSAMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos A & B BSA", "label": "Kreos A & B BSA [Member]", "documentation": "Kreos A & B BSA" } } }, "auth_ref": [] }, "abvx_KreosABCBSAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "KreosABCBSAMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos A & B & C BSA", "label": "Kreos A & B & C BSA [Member]", "documentation": "Kreos A & B & C BSA" } } }, "auth_ref": [] }, "abvx_KreosCBSAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "KreosCBSAMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos C BSA", "label": "Kreos C BSA [Member]", "documentation": "Kreos C BSA" } } }, "auth_ref": [] }, "abvx_KreosClaretBondLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "KreosClaretBondLoansMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos & Claret bond loans", "label": "Kreos & Claret Bond Loans [Member]", "documentation": "Kreos & Claret Bond Loans" } } }, "auth_ref": [] }, "abvx_KreosClaretFinancingBSAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "KreosClaretFinancingBSAMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos / Claret BSA", "label": "Kreos & Claret Financing, BSA [Member]", "documentation": "Kreos & Claret Financing, BSA" } } }, "auth_ref": [] }, "abvx_KreosClaretFinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "KreosClaretFinancingMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos & Claret financing", "label": "Kreos & Claret Financing [Member]", "documentation": "Kreos & Claret Financing" } } }, "auth_ref": [] }, "abvx_KreosClaretFinancingTrancheABAndCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "KreosClaretFinancingTrancheABAndCMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos & Claret Financing, Tranche A,B and C", "label": "Kreos & Claret Financing, Tranche A,B and C [Member]", "documentation": "Kreos & Claret Financing, Tranche A,B and C" } } }, "auth_ref": [] }, "abvx_KreosClaretFinancingTrancheABMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "KreosClaretFinancingTrancheABMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos & Claret Financing, Tranche A-B", "label": "Kreos & Claret Financing, Tranche A-B [Member]", "documentation": "Kreos & Claret Financing, Tranche A-B" } } }, "auth_ref": [] }, "abvx_KreosClaretFinancingTrancheAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "KreosClaretFinancingTrancheAMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos / Claret convertible notes (OCABSA)", "netLabel": "Kreos/Claret BSA", "label": "Kreos & Claret Financing, Tranche A [Member]", "documentation": "Kreos & Claret Financing, Tranche A" } } }, "auth_ref": [] }, "abvx_KreosClaretFinancingTrancheBAndCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "KreosClaretFinancingTrancheBAndCMember", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos & Claret Financing, Tranche B and C", "label": "Kreos & Claret Financing, Tranche B and C [Member]", "documentation": "Kreos & Claret Financing, Tranche B and C" } } }, "auth_ref": [] }, "abvx_KreosClaretFinancingTrancheBMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "KreosClaretFinancingTrancheBMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos & Claret financing, tranche B", "label": "Kreos & Claret Financing, Tranche B [Member]", "documentation": "Kreos & Claret Financing, Tranche B" } } }, "auth_ref": [] }, "abvx_KreosClaretFinancingTrancheCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "KreosClaretFinancingTrancheCMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos & Claret financing, tranche C", "label": "Kreos & Claret Financing, Tranche C [Member]", "documentation": "Kreos & Claret Financing, Tranche C" } } }, "auth_ref": [] }, "abvx_KreosClaretMinimumReturnIndemnificationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "KreosClaretMinimumReturnIndemnificationsMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos/Claret Minimum Return Indemnifications", "label": "Kreos & Claret Minimum Return Indemnifications [Member]", "documentation": "Kreos & Claret Minimum Return Indemnifications" } } }, "auth_ref": [] }, "ifrs-full_LaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LaterThanFiveYearsMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "LONGER THAN 5 YEARS", "label": "Later than five years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than five years." } } }, "auth_ref": [ "r117", "r118", "r127", "r210", "r213", "r215" ] }, "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "FROM 1 TO 2 YEARS", "label": "Later than one year and not later than two years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than two years." } } }, "auth_ref": [ "r117", "r118", "r127", "r210", "r215", "r224" ] }, "ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LaterThanTwoYearsAndNotLaterThanFiveYearsMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "FROM 2 TO 5 YEARS", "label": "Later than two years and not later than five years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than two years and not later than five years." } } }, "auth_ref": [ "r224" ] }, "abvx_LeaseFacilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "LeaseFacilitiesMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease facilities", "label": "Lease Facilities [Member]", "documentation": "Lease Facilities" } } }, "auth_ref": [] }, "ifrs-full_LeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LeaseLiabilities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofvariationinleaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Lease liabilities at beginning of period", "periodEndLabel": "Lease liabilities at end of period", "terseLabel": "Lease liabilities", "label": "Lease liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } } }, "auth_ref": [ "r112" ] }, "ifrs-full_LeaseLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LeaseLiabilitiesMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities", "label": "Lease liabilities [member]" } }, "en": { "role": { "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r189", "r192" ] }, "abvx_LeaseLiabilityPercentageOfTotal": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "LeaseLiabilityPercentageOfTotal", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liability, percentage of total", "label": "Lease Liability, Percentage Of Total", "documentation": "Lease Liability, Percentage Of Total" } } }, "auth_ref": [] }, "ifrs-full_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "Liabilities", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities", "label": "Liabilities" } }, "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r15", "r102", "r103", "r105", "r162", "r165" ] }, "ifrs-full_LiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Liabilities arising from financing activities at beginning of period", "periodEndLabel": "Liabilities arising from financing activities at end of period", "label": "Liabilities arising from financing activities" } }, "en": { "role": { "documentation": "The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]" } } }, "auth_ref": [ "r190" ] }, "ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LiabilitiesArisingFromFinancingActivitiesAxis", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities arising from financing activities [axis]", "label": "Liabilities arising from financing activities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r190" ] }, "ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LiabilitiesArisingFromFinancingActivitiesDomain", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities arising from financing activities [domain]", "label": "Liabilities arising from financing activities [domain]" } }, "en": { "role": { "documentation": "This member stands for liabilities arising from financing activities. It also represents the standard value for the 'Liabilities arising from financing activities' axis if no other member is used. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r190" ] }, "ifrs-full_LicencesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LicencesMember", "presentation": [ "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "LICENCES", "label": "Licences [member]" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets representing the right to use certain intangible assets owned by another entity. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r238" ] }, "ifrs-full_LongtermDeposits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LongtermDeposits", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails": { "parentTag": "ifrs-full_OtherNoncurrentFinancialAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deposits", "label": "Long-term deposits" } }, "en": { "role": { "documentation": "The amount of long-term deposits held by the entity." } } }, "auth_ref": [ "r226" ] }, "ifrs-full_LossesOnChangeInFairValueOfDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LossesOnChangeInFairValueOfDerivatives", "crdr": "debit", "calculation": { "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Increase in fair value", "negatedTerseLabel": "Increase in derivatives fair value", "label": "Losses on change in fair value of derivatives" } }, "en": { "role": { "documentation": "The losses resulting from changes in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]" } } }, "auth_ref": [ "r230" ] }, "abvx_LossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "LossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss", "crdr": "debit", "calculation": { "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Increase in other liabilities at fair value through profit and loss", "label": "Losses On Financial Liabilities At Fair Value Through Profit Or Loss", "documentation": "Losses On Financial Liabilities At Fair Value Through Profit Or Loss" } } }, "auth_ref": [] }, "ifrs-full_MachineryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "MachineryMember", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "EQUIPMENT", "label": "Machinery [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing long-lived, depreciable machinery used in operations. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r179" ] }, "abvx_MajorRevenueTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "MajorRevenueTransactionsMember", "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Major revenue transactions", "label": "Major Revenue Transactions [Member]", "documentation": "Major Revenue Transactions" } } }, "auth_ref": [] }, "abvx_MajorShareBasedTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "MajorShareBasedTransactionsMember", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Major share-based transactions", "label": "Major Share-Based Transactions [Member]", "documentation": "Major Share-Based Transactions" } } }, "auth_ref": [] }, "ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "MaturityAnalysisForDerivativeFinancialLiabilities", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of remaining contractual maturities of derivative financial liabilities", "label": "Disclosure of maturity analysis for derivative financial liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of a maturity analysis for derivative financial liabilities, including the remaining contractual maturities for those derivative financial liabilities for which contractual maturities are essential for an understanding of the timing of the cash flows. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r148" ] }, "ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "MaturityAnalysisForNonderivativeFinancialLiabilities", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of remaining contractual maturities of non-derivative financial liabilities", "label": "Disclosure of maturity analysis for non-derivative financial liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of a maturity analysis for non-derivative financial liabilities (including issued financial guarantee contracts) that shows the remaining contractual maturities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r147" ] }, "ifrs-full_MaturityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "MaturityAxis", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity [axis]", "label": "Maturity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r17", "r109", "r117", "r118", "r119", "r120", "r121", "r127", "r138", "r149", "r181", "r210" ] }, "ifrs-full_MaturityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "MaturityDomain", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity [domain]", "label": "Maturity [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } } }, "auth_ref": [ "r17", "r109", "r117", "r118", "r119", "r120", "r121", "r127", "r138", "r181", "r210", "r214" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureoffairvalueoftheBSAsatgrantdateusingtheBlackScholesmodelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [] }, "abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet": { "xbrltype": "sharesItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum number of shares to be issued if all conditions are met (in shares)", "label": "Maximum Number Of Other Equity Instruments To Be Issued In Share-Based Payment Arrangement If All Conditions Are Met", "documentation": "Maximum Number Of Other Equity Instruments To Be Issued In Share-Based Payment Arrangement If All Conditions Are Met" } } }, "auth_ref": [] }, "ifrs-full_MeasurementAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "MeasurementAxis", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement [axis]", "label": "Measurement [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r71", "r75", "r102" ] }, "ifrs-full_MeasurementDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "MeasurementDomain", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement [domain]", "label": "Measurement [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used." } } }, "auth_ref": [ "r71", "r75", "r102" ] }, "abvx_MinimalReturnMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "MinimalReturnMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimal return", "label": "Minimal Return, Measurement Input [Member]", "documentation": "Minimal Return, Measurement Input" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureoffairvalueoftheBSAsatgrantdateusingtheBlackScholesmodelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [] }, "ifrs-full_MiscellaneousOtherOperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "MiscellaneousOtherOperatingExpense", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abivax.com/role/OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails", "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails", "http://www.abivax.com/role/OperatingexpensesDisclosureofsalesandmarketingexpensesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other sales and marketing expenses", "terseLabel": "Other research and development expenses", "netLabel": "Other general and administrative expenses", "label": "Miscellaneous other operating expense" } }, "en": { "role": { "documentation": "The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]" } } }, "auth_ref": [ "r224" ] }, "ifrs-full_MiscellaneousOtherOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "MiscellaneousOtherOperatingIncome", "crdr": "credit", "calculation": { "http://www.abivax.com/role/OperatingincomeDisclosureofbreakdownofoperatingincomeDetails": { "parentTag": "ifrs-full_OtherIncome", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/OperatingincomeDisclosureofbreakdownofoperatingincomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Miscellaneous other operating income" } }, "en": { "role": { "documentation": "The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]" } } }, "auth_ref": [ "r224" ] }, "abvx_MonteCarloModelMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "MonteCarloModelMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Monte Carlo model", "label": "Monte Carlo Model [Member]", "documentation": "Monte Carlo Model" } } }, "auth_ref": [] }, "abvx_NetProceedsFromNonConvertibleLoansNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "NetProceedsFromNonConvertibleLoansNotes", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from non-convertible bond loans", "label": "Net Proceeds From Non-Convertible Loans Notes", "documentation": "Net Proceeds From Non-Convertible Loans Notes" } } }, "auth_ref": [] }, "abvx_NetProceedsFromSaleOfRoyaltyCertificates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "NetProceedsFromSaleOfRoyaltyCertificates", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from sale of royalty certificate", "label": "Net Proceeds From Sale Of Royalty Certificates", "documentation": "Net Proceeds From Sale Of Royalty Certificates" } } }, "auth_ref": [] }, "abvx_NonCurrentAdvancesToCROContracts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "NonCurrentAdvancesToCROContracts", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails": { "parentTag": "ifrs-full_OtherNoncurrentFinancialAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advances related to CRO contracts", "label": "Non-Current Advances To CRO Contracts", "documentation": "Non-Current Advances To CRO Contracts" } } }, "auth_ref": [] }, "abvx_NonCurrentAdvancesToCROContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "NonCurrentAdvancesToCROContractsMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term advances made to CROs", "label": "Non-Current Advances To CRO Contracts [Member]", "documentation": "Non-Current Advances To CRO Contracts" } } }, "auth_ref": [] }, "abvx_NonCurrentConvertibleLoansNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "NonCurrentConvertibleLoansNotes", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible loan notes", "label": "Non-Current Convertible Loans Notes", "documentation": "Non-Current Convertible Loans Notes" } } }, "auth_ref": [] }, "abvx_NonCurrentFinancialLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "NonCurrentFinancialLiabilitiesMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities-non current portion", "label": "Non-Current Financial Liabilities [Member]", "documentation": "Non-Current Financial Liabilities" } } }, "auth_ref": [] }, "abvx_NonCurrentPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "NonCurrentPrepaidExpenses", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails": { "parentTag": "ifrs-full_OtherNoncurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses - non current", "label": "Non-Current Prepaid Expenses", "documentation": "Non-Current Prepaid Expenses" } } }, "auth_ref": [] }, "abvx_NonCurrentRoyaltyCertificates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "NonCurrentRoyaltyCertificates", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 3.0 }, "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails", "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty certificates", "label": "Non-Current Royalty Certificates", "documentation": "Non-Current Royalty Certificates" } } }, "auth_ref": [] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodAxis", "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-adjusting events after reporting period [axis]", "label": "Non-adjusting events after reporting period [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r34" ] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodDomain", "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-adjusting events after reporting period [domain]", "label": "Non-adjusting events after reporting period [domain]" } }, "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } } }, "auth_ref": [ "r34" ] }, "ifrs-full_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NoncurrentAssets", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current assets", "label": "Non-current assets" } }, "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } } }, "auth_ref": [ "r18", "r94", "r193" ] }, "ifrs-full_NoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NoncurrentAssetsAbstract", "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current assets", "label": "Non-current assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentDerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NoncurrentDerivativeFinancialLiabilities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative instruments", "label": "Non-current derivative financial liabilities" } }, "en": { "role": { "documentation": "The amount of non-current derivative financial liabilities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r226" ] }, "ifrs-full_NoncurrentFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NoncurrentFinancialLiabilities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Non-current financial liabilities", "label": "Non-current financial liabilities" } }, "en": { "role": { "documentation": "The amount of non-current financial liabilities. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r139" ] }, "ifrs-full_NoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NoncurrentLiabilities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current liabilities", "label": "Non-current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } } }, "auth_ref": [ "r19", "r96", "r193" ] }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NoncurrentLiabilitiesAbstract", "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current liabilities", "label": "Non-current liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NoncurrentPortionOfOtherNoncurrentBorrowings", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings", "label": "Non-current portion of other non-current borrowings" } }, "en": { "role": { "documentation": "The non-current portion of non-current other borrowings. [Refer: Other borrowings]" } } }, "auth_ref": [ "r224" ] }, "ifrs-full_NoncurrentProvisionsForEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NoncurrentProvisionsForEmployeeBenefits", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement benefit obligations", "label": "Non-current provisions for employee benefits" } }, "en": { "role": { "documentation": "The amount of non-current provisions for employee benefits. [Refer: Provisions for employee benefits]" } } }, "auth_ref": [ "r21" ] }, "ifrs-full_NotLaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NotLaterThanOneYearMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "LESS THAN 1 YEAR", "label": "Not later than one year [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } } }, "auth_ref": [ "r16", "r117", "r118", "r127", "r210", "r215" ] }, "ifrs-full_NotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NotionalAmount", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Original principal amount", "label": "Notional amount" } }, "en": { "role": { "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument." } } }, "auth_ref": [ "r224" ] }, "abvx_NumberOfADSPerOrdinaryShares": { "xbrltype": "integerItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "NumberOfADSPerOrdinaryShares", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Number of ADS per Ordinary Shares", "label": "Number of ADS per Ordinary Shares", "documentation": "Number of ADS per Ordinary Shares" } } }, "auth_ref": [] }, "abvx_NumberOfConvertibleNotesOutstanding": { "xbrltype": "integerItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "NumberOfConvertibleNotesOutstanding", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of outstanding notes (in shares)", "label": "Number Of Convertible Notes Outstanding", "documentation": "Number Of Convertible Notes Outstanding" } } }, "auth_ref": [] }, "abvx_NumberOfFreeSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "NumberOfFreeSharesIssued", "presentation": [ "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails", "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issue of free shares (in shares)", "label": "Number Of Free Shares Issued", "documentation": "Number Of Free Shares Issued" } } }, "auth_ref": [] }, "abvx_NumberOfFreeSharesPlansIssued": { "xbrltype": "integerItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "NumberOfFreeSharesPlansIssued", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsForthethreemonthsendedMarch312025Details", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Number of free shares plans issued", "label": "Number Of Free Shares Plans Issued", "documentation": "Number Of Free Shares Plans Issued" } } }, "auth_ref": [] }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureoffairvalueoftheBSAsatgrantdateusingtheBlackScholesmodelDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsForthethreemonthsendedMarch312025Details", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of instruments issued (in shares)", "netLabel": "NUMBER OF BSAs (in shares)", "label": "Number of other equity instruments granted in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } } }, "auth_ref": [ "r131", "r249" ] }, "abvx_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.abivax.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number Of Operating Segments", "documentation": "Number Of Operating Segments" } } }, "auth_ref": [] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of instruments exercisable (in shares)", "label": "Number of other equity instruments exercisable in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement." } } }, "auth_ref": [ "r249" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of instruments exercised (in shares)", "negatedTerseLabel": "Number of instruments exercised (in shares)", "negatedLabel": "Number of instruments vested (in shares)", "label": "Number of other equity instruments exercised or vested in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement." } } }, "auth_ref": [ "r249" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Number of instruments lapsed (in shares)", "label": "Number of other equity instruments expired in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) expired in a share-based payment arrangement." } } }, "auth_ref": [ "r249" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of instruments outstanding, beginning balance (in shares)", "periodEndLabel": "Number of instruments outstanding, ending balance (in shares)", "label": "Number of other equity instruments outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r249" ] }, "abvx_NumberOfProbabilityWeightedScenarios": { "xbrltype": "integerItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "NumberOfProbabilityWeightedScenarios", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of probability-weighted scenarios", "label": "Number Of Probability-Weighted Scenarios", "documentation": "Number Of Probability-Weighted Scenarios" } } }, "auth_ref": [] }, "ifrs-full_NumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NumberOfSharesIssued", "presentation": [ "http://www.abivax.com/role/ShareholdersequitySharecapitalissuedDetails", "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of shares issued at beginning of period (in shares)", "periodEndLabel": "Number of shares issued at end of period (in shares)", "terseLabel": "Number of shares issued (in shares)", "label": "Number of shares issued" } }, "en": { "role": { "documentation": "The number of shares issued by the entity." } } }, "auth_ref": [ "r222" ] }, "ifrs-full_NumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NumberOfSharesOutstanding", "presentation": [ "http://www.abivax.com/role/ShareholdersequitySharecapitalissuedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares outstanding (in shares)", "label": "Number of shares outstanding" } }, "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } } }, "auth_ref": [ "r24" ] }, "abvx_NumberOfTreasurySharesHeld": { "xbrltype": "sharesItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "NumberOfTreasurySharesHeld", "presentation": [ "http://www.abivax.com/role/ShareholdersequitySharecapitalissuedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of treasury shares held (in shares)", "label": "Number Of Treasury Shares Held", "documentation": "Number Of Treasury Shares Held" } } }, "auth_ref": [] }, "abvx_NumberOfWarrantsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "NumberOfWarrantsGranted", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of warrants granted (in shares)", "label": "Number Of Warrants Granted", "documentation": "Number Of Warrants Granted" } } }, "auth_ref": [] }, "abvx_NumberOfWarrantsOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "NumberOfWarrantsOutstanding", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of outstanding warrants (in shares)", "label": "Number Of Warrants Outstanding", "documentation": "Number Of Warrants Outstanding" } } }, "auth_ref": [] }, "abvx_NumberOfWarrantsOutstandingSubjectToNonMarketPerformanceCondition": { "xbrltype": "sharesItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "NumberOfWarrantsOutstandingSubjectToNonMarketPerformanceCondition", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of outstanding warrants subject to non-market performance condition (in shares)", "label": "Number Of Warrants Outstanding Subject To Non-Market Performance Condition", "documentation": "Number Of Warrants Outstanding Subject To Non-Market Performance Condition" } } }, "auth_ref": [] }, "abvx_OffBalanceSheetCommitmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "OffBalanceSheetCommitmentsAbstract", "lang": { "en-us": { "role": { "label": "Off-Balance Sheet Commitments [Abstract]", "documentation": "Off-Balance Sheet Commitments" } } }, "auth_ref": [] }, "ifrs-full_OperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OperatingExpense", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFLOSS": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 2.0 }, "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails", "http://www.abivax.com/role/OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails", "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails", "http://www.abivax.com/role/OperatingexpensesDisclosureofsalesandmarketingexpensesDetails", "http://www.abivax.com/role/OperatingexpensesNarrativeDetails", "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFLOSS" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total operating expenses", "totalLabel": "Operating expenses", "terseLabel": "Operating expense", "label": "Operating expense" } }, "en": { "role": { "documentation": "The amount of all operating expenses." } } }, "auth_ref": [ "r230" ] }, "ifrs-full_OptionPricingModelMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OptionPricingModelMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option pricing model", "label": "Option pricing model [member]" } }, "en": { "role": { "documentation": "This member stands for a specific valuation technique consistent with the income approach that involves analysing future amounts with option pricing models, such as the Black-Scholes-Merton formula or a binominal model (ie a lattice model), that incorporate present value techniques and reflect both the time value and intrinsic value of an option. [Refer: Income approach [member]]" } } }, "auth_ref": [ "r197", "r202" ] }, "ifrs-full_OtherAdjustmentsForNoncashItems": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherAdjustmentsForNoncashItems", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other adjustments for non-cash items" } }, "en": { "role": { "documentation": "Adjustments for non-cash items to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r243" ] }, "ifrs-full_OtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherAssets", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Other receivables and other assets", "label": "Other assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r226" ] }, "ifrs-full_OtherCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/CashandcashequivalentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notice accounts", "label": "Other cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of cash and cash equivalents that the entity does not separately disclose in the same statement or note. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r245" ] }, "ifrs-full_OtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherComprehensiveIncome", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive (loss) income", "terseLabel": "Other comprehensive income", "label": "Other comprehensive income" } }, "en": { "role": { "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]" } } }, "auth_ref": [ "r3", "r28", "r32", "r98" ] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation differences", "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r20", "r32" ] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Actuarial gains on retirement benefit obligations", "label": "Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [domain]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]" } } }, "auth_ref": [ "r20", "r32", "r234" ] }, "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Items that are or may be reclassified subsequently to profit or loss", "label": "Other comprehensive income that will be reclassified to profit or loss, net of tax" } }, "en": { "role": { "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r177", "r178" ] }, "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Items that will not be reclassified to profit or loss", "label": "Other comprehensive income that will not be reclassified to profit or loss, net of tax" } }, "en": { "role": { "documentation": "The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r177", "r178" ] }, "ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings", "label": "Other current borrowings and current portion of other non-current borrowings" } }, "en": { "role": { "documentation": "The amount of current other borrowings and the current portion of non-current other borrowings. [Refer: Other borrowings]" } } }, "auth_ref": [ "r224" ] }, "ifrs-full_OtherCurrentFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherCurrentFinancialAssets", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 1.0 }, "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails": { "parentTag": "ifrs-full_OtherFinancialAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails", "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Other financial assets", "totalLabel": "Total other current financial assets", "label": "Other current financial assets" } }, "en": { "role": { "documentation": "The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]" } } }, "auth_ref": [ "r12" ] }, "ifrs-full_OtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherCurrentPayables", "crdr": "credit", "calculation": { "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureofbreakdownoftradeandotherpayablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureofbreakdownoftradeandotherpayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other current payables" } }, "en": { "role": { "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r226" ] }, "ifrs-full_OtherFinanceCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherFinanceCost", "crdr": "debit", "calculation": { "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other", "label": "Other finance cost" } }, "en": { "role": { "documentation": "The amount of finance costs that the entity does not separately disclose in the same statement or note. [Refer: Finance costs]" } } }, "auth_ref": [ "r224" ] }, "ifrs-full_OtherFinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherFinanceIncome", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other financial income", "label": "Other finance income" } }, "en": { "role": { "documentation": "The amount of finance income that the entity does not separately disclose in the same statement or note. [Refer: Finance income]" } } }, "auth_ref": [ "r224" ] }, "ifrs-full_OtherFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherFinancialAssets", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Other financial assets", "label": "Other financial assets" } }, "en": { "role": { "documentation": "The amount of financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]" } } }, "auth_ref": [ "r12" ] }, "abvx_OtherFinancialAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "OtherFinancialAssetsMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other financial assets", "label": "Other Financial Assets [Member]", "documentation": "Other Financial Assets" } } }, "auth_ref": [] }, "abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "OtherFinancialLiabilitiesMaximumDrawdownCapacity", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum drawdown capacity", "label": "Other Financial Liabilities, Maximum Drawdown Capacity", "documentation": "Other Financial Liabilities, Maximum Drawdown Capacity" } } }, "auth_ref": [] }, "abvx_OtherFinancialLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "OtherFinancialLiabilitiesMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other financial liabilities", "label": "Other Financial Liabilities [Member]", "documentation": "Other Financial Liabilities" } } }, "auth_ref": [] }, "ifrs-full_OtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherIncome", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFLOSS": { "parentTag": "ifrs-full_RevenueAndOperatingIncome", "weight": 1.0, "order": 1.0 }, "http://www.abivax.com/role/OperatingincomeDisclosureofbreakdownofoperatingincomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/OperatingincomeDisclosureofbreakdownofoperatingincomeDetails", "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFLOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Other operating income", "totalLabel": "Total operating income", "label": "Other income" } }, "en": { "role": { "documentation": "The amount of operating income that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r49", "r172", "r173" ] }, "ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other inflows (outflows) of cash, classified as financing activities" } }, "en": { "role": { "documentation": "Inflows (outflows) of cash, classified as financing activities, that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r79" ] }, "ifrs-full_OtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherIntangibleAssetsMember", "presentation": [ "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OTHER INTANGIBLE ASSETS", "label": "Other intangible assets [member]" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r238" ] }, "abvx_OtherKreosClaretBondLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "OtherKreosClaretBondLoansMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Kreos/Claret bond loans", "label": "Other Kreos, Claret Bond Loans [Member]", "documentation": "Other Kreos, Claret Bond Loans" } } }, "auth_ref": [] }, "ifrs-full_OtherLongtermProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherLongtermProvisions", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions", "label": "Other non-current provisions" } }, "en": { "role": { "documentation": "The amount of non-current provisions other than provisions for employee benefits. [Refer: Non-current provisions]" } } }, "auth_ref": [ "r21" ] }, "abvx_OtherNonCurrentMiscellaneousFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "OtherNonCurrentMiscellaneousFinancialAssets", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails": { "parentTag": "ifrs-full_OtherNoncurrentFinancialAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Non-Current Miscellaneous Financial Assets", "documentation": "Other Non-Current Miscellaneous Financial Assets" } } }, "auth_ref": [] }, "ifrs-full_OtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails": { "parentTag": "ifrs-full_OtherAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current other assets", "label": "Other non-current assets" } }, "en": { "role": { "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]" } } }, "auth_ref": [ "r226" ] }, "ifrs-full_OtherNoncurrentFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherNoncurrentFinancialAssets", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails": { "parentTag": "ifrs-full_OtherFinancialAssets", "weight": 1.0, "order": 2.0 }, "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails", "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Other financial assets", "totalLabel": "Total other non-current financial assets", "label": "Other non-current financial assets" } }, "en": { "role": { "documentation": "The amount of non-current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets]" } } }, "auth_ref": [ "r12" ] }, "ifrs-full_OtherNoncurrentNonfinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherNoncurrentNonfinancialAssets", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other non-current non-financial assets" } }, "en": { "role": { "documentation": "The amount of non-current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]" } } }, "auth_ref": [ "r226" ] }, "abvx_OtherReceivablesAndAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "OtherReceivablesAndAssetsMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables and assets", "label": "Other Receivables And Assets [Member]", "documentation": "Other Receivables And Assets" } } }, "auth_ref": [] }, "ifrs-full_OtherShorttermProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherShorttermProvisions", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions", "label": "Other current provisions" } }, "en": { "role": { "documentation": "The amount of current provisions other than provisions for employee benefits. [Refer: Provisions]" } } }, "auth_ref": [ "r21" ] }, "ifrs-full_ParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ParValuePerShare", "presentation": [ "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails", "http://www.abivax.com/role/ShareholdersequitySharecapitalissuedDetails", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Par value per share (in euro per share)", "label": "Par value per share" } }, "en": { "role": { "documentation": "The nominal value per share." } } }, "auth_ref": [ "r23" ] }, "ifrs-full_PaymentsForDebtIssueCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "PaymentsForDebtIssueCosts", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments for debt issue costs", "label": "Payments for debt issue costs" } }, "en": { "role": { "documentation": "The cash outflow for debt issue costs." } } }, "auth_ref": [ "r241" ] }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments of the lease liabilities", "label": "Payments of lease liabilities, classified as financing activities" } }, "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r188" ] }, "abvx_PeakPenetrationMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "PeakPenetrationMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Peak penetration", "label": "Peak Penetration, Measurement Input [Member]", "documentation": "Peak Penetration, Measurement Input" } } }, "auth_ref": [] }, "abvx_PercentageOfConditionalAdvancesWaived": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "PercentageOfConditionalAdvancesWaived", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of conditional advances waived", "label": "Percentage Of Conditional Advances Waived", "documentation": "Percentage Of Conditional Advances Waived" } } }, "auth_ref": [] }, "abvx_PercentageOfDecreaseInTheOperatingExpenses": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "PercentageOfDecreaseInTheOperatingExpenses", "presentation": [ "http://www.abivax.com/role/OperatingexpensesNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Percentage of decrease in the operating expenses", "label": "Percentage Of Decrease In the Operating Expenses", "documentation": "Percentage Of Decrease In the Operating Expenses" } } }, "auth_ref": [] }, "ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Percentage of reasonably possible decrease in unobservable input, liabilities", "label": "Percentage of reasonably possible decrease in unobservable input, liabilities" } }, "en": { "role": { "documentation": "The percentage of a reasonably possible decrease in an unobservable input used in fair value measurement of liabilities." } } }, "auth_ref": [ "r247" ] }, "ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of reasonably possible increase in unobservable input, assets", "label": "Percentage of reasonably possible increase in unobservable input, assets" } }, "en": { "role": { "documentation": "The percentage of a reasonably possible increase in an unobservable input used in fair value measurement of assets." } } }, "auth_ref": [ "r247" ] }, "ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of reasonably possible increase in unobservable input, liabilities", "label": "Percentage of reasonably possible increase in unobservable input, liabilities" } }, "en": { "role": { "documentation": "The percentage of a reasonably possible increase in an unobservable input used in fair value measurement of liabilities." } } }, "auth_ref": [ "r247" ] }, "abvx_PretGarantiParLEtatPGEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "PretGarantiParLEtatPGEMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PGE", "label": "Pr\u00eat Garanti Par l'Etat (PGE) [Member]", "documentation": "Pr\u00eat Garanti Par l'Etat (PGE)" } } }, "auth_ref": [] }, "abvx_PrincipalAgreementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "PrincipalAgreementsAxis", "presentation": [ "http://www.abivax.com/role/IntangibleassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal Agreements [Axis]", "label": "Principal Agreements [Axis]", "documentation": "Principal Agreements" } } }, "auth_ref": [] }, "abvx_PrincipalAgreementsDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "PrincipalAgreementsDomain", "presentation": [ "http://www.abivax.com/role/IntangibleassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal Agreements [Domain]", "label": "Principal Agreements [Domain]", "documentation": "Principal Agreements [Domain]" } } }, "auth_ref": [] }, "abvx_ProbabilityOfSuccessMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "ProbabilityOfSuccessMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "POS", "label": "Probability Of Success, Measurement Input [Member]", "documentation": "Probability Of Success, Measurement Input" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from borrowings", "label": "Proceeds from borrowings, classified as financing activities" } }, "en": { "role": { "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]" } } }, "auth_ref": [ "r187" ] }, "abvx_ProceedsFromConditionalAdvances": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "ProceedsFromConditionalAdvances", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from conditional advances", "label": "Proceeds From Conditional Advances", "documentation": "Proceeds From Conditional Advances" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from government grants", "label": "Proceeds from government grants, classified as financing activities" } }, "en": { "role": { "documentation": "The cash inflow from government grants, classified as financing activities. [Refer: Government [member]; Government grants]" } } }, "auth_ref": [ "r235" ] }, "ifrs-full_ProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ProceedsFromIssuingShares", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital increases", "label": "Proceeds from issuing shares" } }, "en": { "role": { "documentation": "The cash inflow from issuing shares." } } }, "auth_ref": [ "r186" ] }, "abvx_ProceedsFromReimbursementsOfDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "ProceedsFromReimbursementsOfDeposits", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease in Deposits", "label": "Proceeds From Reimbursements Of Deposits", "documentation": "Proceeds From Reimbursements Of Deposits" } } }, "auth_ref": [] }, "abvx_ProceedsFromResearchTaxCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "ProceedsFromResearchTaxCredit", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails", "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from research tax credit", "label": "Proceeds From Research Tax Credit", "documentation": "Proceeds From Research Tax Credit" } } }, "auth_ref": [] }, "ifrs-full_ProfessionalFeesExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ProfessionalFeesExpense", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails", "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails", "http://www.abivax.com/role/OperatingexpensesDisclosureofsalesandmarketingexpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consulting and professional fees", "label": "Professional fees expense" } }, "en": { "role": { "documentation": "The amount of fees paid or payable for professional services." } } }, "auth_ref": [ "r224" ] }, "ifrs-full_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 }, "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 1.0 }, "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFLOSS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails", "http://www.abivax.com/role/IncomelosspershareDetails", "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFLOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss for the period", "terseLabel": "Net loss for the period", "negatedTerseLabel": "Net loss for the period", "label": "Profit (loss)" } }, "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r2", "r27", "r78", "r90", "r92", "r162", "r163", "r193", "r205" ] }, "ifrs-full_ProfitLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ProfitLossBeforeTax", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFLOSS": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFLOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss before tax", "label": "Profit (loss) before tax" } }, "en": { "role": { "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r135", "r172", "r173", "r217", "r218" ] }, "ifrs-full_ProfitLossFromOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ProfitLossFromOperatingActivities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFLOSS": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFLOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Operating loss", "label": "Profit (loss) from operating activities" } }, "en": { "role": { "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r182", "r230" ] }, "ifrs-full_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, plant and equipment [abstract]" } } }, "auth_ref": [] }, "ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "PropertyPlantAndEquipmentIncludingRightofuseAssets", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails", "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "periodStartLabel": "Property, plant and equipment including right-of-use assets at beginning of period", "periodEndLabel": "Property, plant and equipment including right-of-use assets at end of period", "label": "Property, plant and equipment including right-of-use assets" } }, "en": { "role": { "documentation": "The amount of property, plant and equipment including right-of-use assets whose underlying assets would be presented as property, plant and equipment if they were owned. [Refer: Property, plant and equipment; Right-of-use assets]" } } }, "auth_ref": [ "r111", "r225", "r233" ] }, "ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment including right-of-use assets [axis]", "label": "Property, plant and equipment including right-of-use assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r233" ] }, "ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment including right-of-use assets [domain]", "label": "Property, plant and equipment including right-of-use assets [domain]" } }, "en": { "role": { "documentation": "This member stands for a class of asset representing property, plant and equipment including right-of-use assets whose underlying assets would be presented as property, plant and equipment if they were owned. [Refer: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r233" ] }, "abvx_ProsynergiaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "ProsynergiaMember", "presentation": [ "http://www.abivax.com/role/IntangibleassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prosynergia", "label": "Prosynergia [Member]", "documentation": "Prosynergia" } } }, "auth_ref": [] }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisitions of property, plant and equipment", "label": "Purchase of property, plant and equipment, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r185" ] }, "abvx_RNPVIRConditionalAdvanceBPIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "RNPVIRConditionalAdvanceBPIMember", "presentation": [ "http://www.abivax.com/role/OperatingincomeNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "RNP-VIR conditional advance", "label": "RNP-VIR Conditional Advance, BPI [Member]", "documentation": "RNP-VIR Conditional Advance, BPI" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureoffairvalueoftheBSAsatgrantdateusingtheBlackScholesmodelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [] }, "ifrs-full_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RangeAxis", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/OtherfinancialassetsNarrativeDetails", "http://www.abivax.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range [axis]", "label": "Range [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r86", "r108", "r121", "r129", "r200", "r202", "r250" ] }, "ifrs-full_RangeDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RangeDomain", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/OtherfinancialassetsNarrativeDetails", "http://www.abivax.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range [domain]", "label": "Range [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } } }, "auth_ref": [ "r86", "r108", "r121", "r129", "r200", "r202", "r250" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureoffairvalueoftheBSAsatgrantdateusingtheBlackScholesmodelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [] }, "ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract", "presentation": [ "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of changes in intangible assets other than goodwill [abstract]", "label": "Reconciliation of changes in intangible assets other than goodwill [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of changes in property, plant and equipment [abstract]", "label": "Reconciliation of changes in property, plant and equipment [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ReconciliationOfNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of number of shares outstanding [abstract]", "label": "Reconciliation of number of shares outstanding [abstract]" } } }, "auth_ref": [] }, "ifrs-full_RecurringFairValueMeasurementMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RecurringFairValueMeasurementMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recurring fair value measurement", "label": "Recurring fair value measurement [member]" } }, "en": { "role": { "documentation": "This member stands for fair value measurements which other IFRSs require or permit in the statement of financial position at the end of each reporting period. [Refer: IFRSs [member]]" } } }, "auth_ref": [ "r102" ] }, "abvx_RegisteredDirectOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "RegisteredDirectOfferingMember", "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Registered direct offering", "label": "Registered Direct Offering [Member]", "documentation": "Registered Direct Offering" } } }, "auth_ref": [] }, "ifrs-full_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Related party transactions [abstract]", "label": "Related party transactions [abstract]" } } }, "auth_ref": [] }, "abvx_RepaymentOfExcessConditionalAdvancesClaimed": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "RepaymentOfExcessConditionalAdvancesClaimed", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Repayment of excess conditional advances claimed", "label": "Repayment Of Excess Conditional Advances Claimed", "documentation": "Repayment Of Excess Conditional Advances Claimed" } } }, "auth_ref": [] }, "abvx_RepaymentsOfBondLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "RepaymentsOfBondLoans", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayments of non-convertible bond loans", "label": "Repayments Of Bond Loans", "documentation": "Repayments Of Bond Loans" } } }, "auth_ref": [] }, "abvx_RepaymentsOfConditionalAdvances": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "RepaymentsOfConditionalAdvances", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayments of conditional advances", "label": "Repayments Of Conditional Advances", "documentation": "Repayments Of Conditional Advances" } } }, "auth_ref": [] }, "abvx_RepaymentsOfConvertibleLoansNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "RepaymentsOfConvertibleLoansNotes", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayments of convertible loan notes", "label": "Repayments Of Convertible Loans Notes", "documentation": "Repayments Of Convertible Loans Notes" } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [] }, "ifrs-full_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFLOSS": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFLOSS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Research and development", "label": "Research and development expense" } }, "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } } }, "auth_ref": [ "r69" ] }, "abvx_ResearchAndDevelopmentExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "ResearchAndDevelopmentExpensesMember", "presentation": [ "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails", "http://www.abivax.com/role/OperatingexpensesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development expenses", "label": "Research And Development Expenses [Member]", "documentation": "Research And Development Expenses" } } }, "auth_ref": [] }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ReserveOfExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Translation reserves", "label": "Reserve of exchange differences on translation" } }, "en": { "role": { "documentation": "A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r47" ] }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ReserveOfExchangeDifferencesOnTranslationMember", "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "TRANSLATION RESERVE", "label": "Reserve of exchange differences on translation [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r47", "r174" ] }, "ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RetainedEarningsExcludingProfitLossForReportingPeriod", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained earnings, excluding profit (loss) for reporting period" } }, "en": { "role": { "documentation": "A component of equity representing the entity\u2019s cumulative undistributed earnings or deficit excluding the profit or loss for the reporting period. [Refer: Retained earnings]" } } }, "auth_ref": [ "r228" ] }, "ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriodMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RetainedEarningsExcludingProfitLossForReportingPeriodMember", "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "RETAINED EARNINGS", "label": "Retained earnings, excluding profit (loss) for reporting period [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit, excluding profit or loss for the reporting period. [Refer: Retained earnings [member]]" } } }, "auth_ref": [ "r223" ] }, "ifrs-full_RetainedEarningsProfitLossForReportingPeriod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RetainedEarningsProfitLossForReportingPeriod", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss for the period", "label": "Retained earnings, profit (loss) for reporting period" } }, "en": { "role": { "documentation": "A component of equity representing the entity\u2019s undistributed profit or loss for the reporting period. [Refer: Retained earnings; Profit (loss)]" } } }, "auth_ref": [ "r228" ] }, "ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RetainedEarningsProfitLossForReportingPeriodMember", "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "NET LOSS FOR THE YEAR", "label": "Retained earnings, profit (loss) for reporting period [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing the entity\u2019s undistributed profit or loss for the reporting period. [Refer: Retained earnings [member]; Profit (loss)]" } } }, "auth_ref": [ "r223" ] }, "abvx_RevaluationOfCashEquivalentsMeasuredAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "RevaluationOfCashEquivalentsMeasuredAtFairValue", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Revaluation of cash equivalents measured at fair value", "label": "Revaluation Of Cash Equivalents Measured At Fair Value", "documentation": "Revaluation Of Cash Equivalents Measured At Fair Value" } } }, "auth_ref": [] }, "ifrs-full_RevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RevenueAbstract", "lang": { "en-us": { "role": { "label": "Revenue [abstract]" } } }, "auth_ref": [] }, "ifrs-full_RevenueAndOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RevenueAndOperatingIncome", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFLOSS": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFLOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating income", "label": "Revenue and other operating income" } }, "en": { "role": { "documentation": "The aggregate amount of the entity's revenue and other operating income. [Refer: Revenue]" } } }, "auth_ref": [ "r230" ] }, "ifrs-full_RevenueFromGovernmentGrants": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RevenueFromGovernmentGrants", "crdr": "credit", "calculation": { "http://www.abivax.com/role/OperatingincomeDisclosureofbreakdownofoperatingincomeDetails": { "parentTag": "ifrs-full_OtherIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/OperatingincomeDisclosureofbreakdownofoperatingincomeDetails", "http://www.abivax.com/role/OperatingincomeNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Subsidies", "label": "Income from government grants" } }, "en": { "role": { "documentation": "The amount of income recognised in relation to government grants. [Refer: Government grants]" } } }, "auth_ref": [ "r236" ] }, "ifrs-full_RevenueFromInterest": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RevenueFromInterest", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Interest income" } }, "en": { "role": { "documentation": "The amount of income arising from interest." } } }, "auth_ref": [ "r100", "r160", "r166", "r224" ] }, "ifrs-full_RightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RightofuseAssets", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets", "label": "Right-of-use assets" } }, "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } } }, "auth_ref": [ "r111", "r114" ] }, "ifrs-full_RightofuseAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RightofuseAssetsMember", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ROU", "label": "Right-of-use assets [member]" } }, "en": { "role": { "documentation": "This member stands for right-of-use assets. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r110" ] }, "abvx_RiskFreeInterestRateMeasurementInputExpiryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "RiskFreeInterestRateMeasurementInputExpiryMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free rate, expiry", "label": "Risk-Free Interest Rate, Measurement Input, Expiry [Member]", "documentation": "Risk-Free Interest Rate, Measurement Input, Expiry" } } }, "auth_ref": [] }, "abvx_RiskFreeInterestRateMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "RiskFreeInterestRateMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free rate", "label": "Risk-Free Interest Rate, Measurement Input [Member]", "documentation": "Risk-Free Interest Rate, Measurement Input" } } }, "auth_ref": [] }, "abvx_RiskFreeInterestRateMeasurementInputTenderOfferMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "RiskFreeInterestRateMeasurementInputTenderOfferMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free, tender offer", "label": "Risk-Free Interest Rate, Measurement Input, Tender Offer [Member]", "documentation": "Risk-Free Interest Rate, Measurement Input, Tender Offer" } } }, "auth_ref": [] }, "abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "RiskFreeInterestRateOtherEquityInstrumentsGranted", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureoffairvalueoftheBSAsatgrantdateusingtheBlackScholesmodelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RISK\u00a0FREE\u00a0RATE", "label": "Risk Free Interest Rate, Other Equity Instruments Granted", "documentation": "Risk Free Interest Rate, Other Equity Instruments Granted" } } }, "auth_ref": [] }, "abvx_RoyaltyCertificateExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "RoyaltyCertificateExpirationPeriod", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty certificate, expiration period", "label": "Royalty Certificate, Expiration Period", "documentation": "Royalty Certificate, Expiration Period" } } }, "auth_ref": [] }, "abvx_RoyaltyCertificateMaximumAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "RoyaltyCertificateMaximumAmount", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty certificate, maximum amount", "label": "Royalty Certificate, Maximum Amount", "documentation": "Royalty Certificate, Maximum Amount" } } }, "auth_ref": [] }, "abvx_RoyaltyCertificatePercentageOfFutureSales": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "RoyaltyCertificatePercentageOfFutureSales", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty certificate, percentage of future sales", "label": "Royalty Certificate, Percentage Of Future Sales", "documentation": "Royalty Certificate, Percentage Of Future Sales" } } }, "auth_ref": [] }, "abvx_RoyaltyCertificatesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "RoyaltyCertificatesMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty certificates", "label": "Royalty Certificates [Member]", "documentation": "Royalty Certificates" } } }, "auth_ref": [] }, "abvx_RoyaltyCertificatesUndiscountedCashFlows": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "RoyaltyCertificatesUndiscountedCashFlows", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": "abvx_FinancialLiabilitiesUndiscountedCashFlows", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty certificates, undiscounted cash flows", "label": "Royalty Certificates, Undiscounted Cash Flows", "documentation": "Royalty Certificates, Undiscounted Cash Flows" } } }, "auth_ref": [] }, "abvx_SaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "SaleOfStockAxis", "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Sale Of Stock [Axis]", "label": "Sale Of Stock [Axis]", "documentation": "Sale Of Stock" } } }, "auth_ref": [] }, "abvx_SaleOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "SaleOfStockDomain", "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Sale Of Stock [Domain]", "label": "Sale Of Stock [Domain]", "documentation": "Sale Of Stock [Domain]" } } }, "auth_ref": [] }, "ifrs-full_SalesAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "SalesAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFLOSS": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFLOSS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Sales and marketing", "label": "Sales and marketing expense" } }, "en": { "role": { "documentation": "The amount of expense relating to the marketing and selling of goods or services." } } }, "auth_ref": [ "r230" ] }, "abvx_SalesAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "SalesAndMarketingExpenseMember", "presentation": [ "http://www.abivax.com/role/OperatingexpensesDisclosureofsalesandmarketingexpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales and marketing expenses", "label": "Sales And Marketing Expense [Member]", "documentation": "Sales And Marketing Expense" } } }, "auth_ref": [] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forecast", "label": "Forecast [Member]" } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Domain]", "label": "Scenario [Domain]" } } }, "auth_ref": [] }, "abvx_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnForeignExchangeGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnForeignExchangeGainLoss", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Reasonably possible change in risk variable, impact on foreign exchange", "label": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Foreign Exchange Gain (Loss)", "documentation": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Foreign Exchange Gain (Loss)" } } }, "auth_ref": [] }, "abvx_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariablePercent": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariablePercent", "presentation": [ "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reasonably possible change in risk variable, percent", "label": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Percent", "documentation": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Percent" } } }, "auth_ref": [] }, "abvx_ShareBasedPaymentArrangementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "ShareBasedPaymentArrangementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangements [Abstract]", "label": "Share-Based Payment Arrangements [Abstract]", "documentation": "Share-Based Payment Arrangements [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_SharePremium": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "SharePremium", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Premiums related to share capital", "label": "Share premium" } }, "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r176" ] }, "ifrs-full_SharePremiumMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "SharePremiumMember", "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "PREMIUMS RELATED TO SHARE CAPITAL", "label": "Share premium [member]" } }, "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r6" ] }, "abvx_SharePriceMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "SharePriceMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary share price (in euro per share)", "verboseLabel": "Share price", "label": "Share Price, Measurement Input [Member]", "documentation": "Share Price, Measurement Input" } } }, "auth_ref": [] }, "abvx_ShareSubscriptionWarrantsBSAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "ShareSubscriptionWarrantsBSAMember", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsForthethreemonthsendedMarch312025Details", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total BSAs", "verboseLabel": "BSAs", "label": "Share Subscription Warrants (BSA) [Member]", "documentation": "Share Subscription Warrants (BSA)" } } }, "auth_ref": [] }, "ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ShorttermDepositsNotClassifiedAsCashEquivalents", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails": { "parentTag": "ifrs-full_OtherCurrentFinancialAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other deposits", "label": "Short-term deposits, not classified as cash equivalents" } }, "en": { "role": { "documentation": "The amount of short-term deposits held by the entity that are not classified as cash equivalents. [Refer: Cash equivalents]" } } }, "auth_ref": [ "r226" ] }, "ifrs-full_ShorttermEmployeeBenefitsAccruals": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ShorttermEmployeeBenefitsAccruals", "crdr": "credit", "calculation": { "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureoftaxandemployeerelatedpayablesDetails": { "parentTag": "abvx_CurrentTaxAndEmployeeBenefitLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureoftaxandemployeerelatedpayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee-related payables", "label": "Short-term employee benefits accruals" } }, "en": { "role": { "documentation": "The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]" } } }, "auth_ref": [ "r229" ] }, "ifrs-full_SignificantUnobservableInputAssets": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "SignificantUnobservableInputAssets", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant unobservable input, assets", "label": "Significant unobservable input, assets" } }, "en": { "role": { "documentation": "The value of significant unobservable input used in the measurement of the fair value of assets." } } }, "auth_ref": [ "r104" ] }, "ifrs-full_SignificantUnobservableInputLiabilities": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "SignificantUnobservableInputLiabilities", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant unobservable input, liabilities", "label": "Significant unobservable input, liabilities" } }, "en": { "role": { "documentation": "The value of significant unobservable input used in the measurement of the fair value of liabilities." } } }, "auth_ref": [ "r104" ] }, "ifrs-full_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of cash flows [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "StatementOfChangesInEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of changes in equity [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "StatementOfChangesInEquityLineItems", "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of changes in equity [line items]", "label": "Statement of changes in equity [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "StatementOfChangesInEquityTable", "presentation": [ "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of changes in equity [table]", "label": "Statement of changes in equity [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } } }, "auth_ref": [ "r6" ] }, "ifrs-full_StatementOfComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "StatementOfComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of comprehensive income [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of financial position [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfIFRSCompliance": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "StatementOfIFRSCompliance", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of compliance", "label": "Statement of IFRS compliance [text block]" } }, "en": { "role": { "documentation": "An explicit and unreserved statement of compliance with all the requirements of IFRSs." } } }, "auth_ref": [ "r8" ] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Axis]", "label": "Scenario [Axis]" } } }, "auth_ref": [] }, "abvx_SubContractingStudiesAndResearchExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "SubContractingStudiesAndResearchExpenses", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sub-contracting, studies and research", "label": "Sub-Contracting, Studies And Research Expenses", "documentation": "Sub-Contracting, Studies And Research Expenses" } } }, "auth_ref": [] }, "ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract", "lang": { "en-us": { "role": { "label": "Subclassifications of assets, liabilities and equities [abstract]" } } }, "auth_ref": [] }, "abvx_TechnologyBasedIntangibleAssetsAssetsAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "TechnologyBasedIntangibleAssetsAssetsAcquisitions", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/IntangibleassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Technology- based intangible assets, assets acquisitions", "label": "Technology- Based Intangible Assets, Assets Acquisitions", "documentation": "Technology- Based Intangible Assets, Assets Acquisitions" } } }, "auth_ref": [] }, "abvx_TenderOfferFairValueOfMRIMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "TenderOfferFairValueOfMRIMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total fair value of MRI, tender offer", "label": "Tender Offer, Fair Value Of MRI , Measurement Input [Member]", "documentation": "Tender Offer, Fair Value Of MRI , Measurement Input" } } }, "auth_ref": [] }, "abvx_TenderOfferProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "TenderOfferProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Probability-weighted present value of shortfall payment, tender offer", "label": "Tender Offer, Probability-Weighted Present Value Of Shortfall Payment, Measurement Input [Member]", "documentation": "Tender Offer, Probability-Weighted Present Value Of Shortfall Payment, Measurement Input" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title and Position [Axis]", "label": "Title and Position [Axis]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title and Position [Domain]", "label": "Title and Position [Domain]" } } }, "auth_ref": [] }, "ifrs-full_TopOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "TopOfRangeMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/OtherfinancialassetsNarrativeDetails", "http://www.abivax.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Top of range", "label": "Top of range [member]" } }, "en": { "role": { "documentation": "This member stands for top of a range." } } }, "auth_ref": [ "r86", "r108", "r121", "r129", "r200", "r202", "r250" ] }, "ifrs-full_TradeAndOtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayables", "crdr": "credit", "calculation": { "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 5.0 }, "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureofbreakdownoftradeandotherpayablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureofbreakdownoftradeandotherpayablesDetails", "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payables and other current liabilities", "totalLabel": "Trade payables and other current liabilities", "label": "Trade and other current payables" } }, "en": { "role": { "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]" } } }, "auth_ref": [ "r14" ] }, "ifrs-full_TradeAndOtherCurrentPayablesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayablesAbstract", "lang": { "en-us": { "role": { "label": "Trade and other current payables [abstract]" } } }, "auth_ref": [] }, "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers", "crdr": "credit", "calculation": { "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureofbreakdownoftradeandotherpayablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureofbreakdownoftradeandotherpayablesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Trade payables", "label": "Current trade payables" } }, "en": { "role": { "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]" } } }, "auth_ref": [ "r175", "r229" ] }, "ifrs-full_TradeAndOtherReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "TradeAndOtherReceivablesAbstract", "lang": { "en-us": { "role": { "label": "Trade and other receivables [abstract]" } } }, "auth_ref": [] }, "abvx_TradePayablesAndOtherCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "TradePayablesAndOtherCurrentLiabilitiesMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payables and other current liabilities", "label": "Trade Payables And Other Current Liabilities [Member]", "documentation": "Trade Payables And Other Current Liabilities" } } }, "auth_ref": [] }, "abvx_TrancheBMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "TrancheBMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche B", "label": "Tranche B [Member]", "documentation": "Tranche B" } } }, "auth_ref": [] }, "abvx_TrancheCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "TrancheCMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche C", "label": "Tranche C [Member]", "documentation": "Tranche C" } } }, "auth_ref": [] }, "abvx_TrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "TrancheOneMember", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsForthethreemonthsendedMarch312025Details", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche 1", "label": "Tranche One [Member]", "documentation": "Tranche One" } } }, "auth_ref": [] }, "abvx_TrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "TrancheThreeMember", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsForthethreemonthsendedMarch312025Details", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche 3", "label": "Tranche Three [Member]", "documentation": "Tranche Three" } } }, "auth_ref": [] }, "abvx_TrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "TrancheTwoMember", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsForthethreemonthsendedMarch312025Details", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche 2", "label": "Tranche Two [Member]", "documentation": "Tranche Two" } } }, "auth_ref": [] }, "abvx_TranchesAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "TranchesAxis", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsForthethreemonthsendedMarch312025Details", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Tranches [Axis]", "label": "Tranches [Axis]", "documentation": "Tranches" } } }, "auth_ref": [] }, "abvx_TranchesDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "TranchesDomain", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsForthethreemonthsendedMarch312025Details", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Tranches [Domain]", "label": "Tranches [Domain]", "documentation": "Tranches [Domain]" } } }, "auth_ref": [] }, "abvx_TransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "TransactionCosts", "crdr": "debit", "calculation": { "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Transaction costs", "label": "Transaction Costs", "documentation": "Transaction Costs" } } }, "auth_ref": [] }, "ifrs-full_TypesOfContractsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "TypesOfContractsAxis", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of contracts [axis]", "label": "Types of contracts [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r204", "r206" ] }, "ifrs-full_TypesOfContractsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "TypesOfContractsDomain", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of contracts [domain]", "label": "Types of contracts [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of contracts with customers. It also represents the standard value for the 'Types of contracts' axis if no other member is used." } } }, "auth_ref": [ "r204", "r206" ] }, "ifrs-full_TypesOfRisksAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "TypesOfRisksAxis", "presentation": [ "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of risks [axis]", "label": "Types of risks [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r122", "r123", "r124", "r126", "r137", "r141", "r142", "r171" ] }, "ifrs-full_TypesOfRisksDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "TypesOfRisksDomain", "presentation": [ "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of risks [domain]", "label": "Types of risks [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used." } } }, "auth_ref": [ "r122", "r123", "r124", "r126", "r137", "r141", "r142", "r171" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsAxis", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureoffairvalueoftheBSAsatgrantdateusingtheBlackScholesmodelDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsForthethreemonthsendedMarch312025Details", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of share-based payment arrangements [axis]", "label": "Types of share-based payment arrangements [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r130" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsDomain", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureoffairvalueoftheBSAsatgrantdateusingtheBlackScholesmodelDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsForthethreemonthsendedMarch312025Details", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of share-based payment arrangements [domain]", "label": "Types of share-based payment arrangements [domain]" } }, "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } } }, "auth_ref": [ "r130" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": [ "http://www.abivax.com/role/EmployeesDetails", "http://www.abivax.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States", "label": "UNITED STATES" } } }, "auth_ref": [] }, "currency_USD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2024", "localname": "USD", "presentation": [ "http://www.abivax.com/role/CashandcashequivalentsNarrativeDetails", "http://www.abivax.com/role/FinancialgainlossNarrativeDetails", "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States of America, Dollars", "label": "United States of America, Dollars" } } }, "auth_ref": [] }, "abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted": { "xbrltype": "perShareItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "UnderlyingShareFairValueOtherEquityInstrumentsGranted", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureoffairvalueoftheBSAsatgrantdateusingtheBlackScholesmodelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "FAIR VALUE OF THE UNDERLYING SHARE (in euro per share)", "label": "Underlying Share Fair Value, Other Equity Instruments Granted", "documentation": "Underlying Share Fair Value, Other Equity Instruments Granted" } } }, "auth_ref": [] }, "ifrs-full_UnobservableInputsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "UnobservableInputsAxis", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unobservable inputs [axis]", "label": "Unobservable inputs [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r104", "r248" ] }, "ifrs-full_UnobservableInputsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "UnobservableInputsDomain", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unobservable inputs [domain]", "label": "Unobservable inputs [domain]" } }, "en": { "role": { "documentation": "This member stands for all the unobservable inputs. It also represents the standard value for the 'Unobservable inputs' axis if no other member is used." } } }, "auth_ref": [ "r104", "r248" ] }, "abvx_UnwindingEffectOfDiscountRelatedToAdvancesMadeToCROs": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "UnwindingEffectOfDiscountRelatedToAdvancesMadeToCROs", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of unwinding the discount related to advances made to CROs", "label": "Unwinding Effect Of Discount Related To Advances Made To CROs", "documentation": "Unwinding Effect Of Discount Related To Advances Made To CROs" } } }, "auth_ref": [] }, "ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ValuationTechniquesUsedInFairValueMeasurementAxis", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation techniques used in fair value measurement [axis]", "label": "Valuation techniques used in fair value measurement [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r104" ] }, "ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ValuationTechniquesUsedInFairValueMeasurementDomain", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation techniques used in fair value measurement [domain]", "label": "Valuation techniques used in fair value measurement [domain]" } }, "en": { "role": { "documentation": "This member stands for valuation techniques used by the entity to measure fair value. It also represents the standard value for the 'Valuation techniques used in fair value measurement' axis if no other member is used. [Refer: At fair value [member]]" } } }, "auth_ref": [ "r104" ] }, "abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "VestingRequirementsForShareBasedPaymentArrangementVestingPercentage", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsForthethreemonthsendedMarch312025Details", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting percentage", "label": "Vesting Requirements For Share-Based Payment Arrangement, Vesting Percentage", "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Vesting Percentage" } } }, "auth_ref": [] }, "abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "VestingRequirementsForShareBasedPaymentArrangementVestingPeriod", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsForthethreemonthsendedMarch312025Details", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsFortheyearended2024Details", "http://www.abivax.com/role/SignificanteventsfortheyearendedDecember312024andthethreemonthsendedMarch312025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting period", "label": "Vesting Requirements For Share-Based Payment Arrangement, Vesting Period", "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Vesting Period" } } }, "auth_ref": [] }, "abvx_VolatilityForSharesMeasurementInputExpiryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "VolatilityForSharesMeasurementInputExpiryMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Volatility, expiry", "label": "Volatility For Shares Measurement Input, Expiry [Member]", "documentation": "Volatility For Shares Measurement Input, Expiry" } } }, "auth_ref": [] }, "abvx_VolatilityForSharesMeasurementInputTenderOfferMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "VolatilityForSharesMeasurementInputTenderOfferMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Volatility, tender offer", "label": "Volatility For Shares Measurement Input, Tender Offer [Member]", "documentation": "Volatility For Shares Measurement Input, Tender Offer" } } }, "auth_ref": [] }, "abvx_VoluntaryConversionScenarioProbabilityMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "VoluntaryConversionScenarioProbabilityMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Held to maturity / voluntary conversion scenario probability", "label": "Voluntary Conversion Scenario Probability, Measurement Input [Member]", "documentation": "Voluntary Conversion Scenario Probability, Measurement Input" } } }, "auth_ref": [] }, "abvx_WarrantsAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "WarrantsAxis", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants [Axis]", "label": "Warrants [Axis]", "documentation": "Warrants" } } }, "auth_ref": [] }, "abvx_WarrantsDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "WarrantsDomain", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants [Domain]", "label": "Warrants [Domain]", "documentation": "Warrants" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageCostOfCapitalMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "WeightedAverageCostOfCapitalMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "WACC", "label": "Weighted average cost of capital, measurement input [member]" } }, "en": { "role": { "documentation": "This member stands for the weighted average cost of capital used as a measurement input." } } }, "auth_ref": [ "r194", "r202" ] }, "ifrs-full_WeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "WeightedAverageShares", "presentation": [ "http://www.abivax.com/role/IncomelosspershareDetails", "http://www.abivax.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFLOSS" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average number of outstanding shares used for computing basic loss per share (in shares)", "terseLabel": "Weighted average number of outstanding shares, basic loss per share (in shares)", "label": "Weighted average number of ordinary shares used in calculating basic earnings per share" } }, "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } } }, "auth_ref": [ "r53" ] }, "abvx_WittycelSASABX196Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20250331", "localname": "WittycelSASABX196Member", "presentation": [ "http://www.abivax.com/role/IntangibleassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Wittycel SAS", "label": "Wittycel SAS - ABX196 [Member]", "documentation": "Wittycel SAS - ABX196" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_104&doctype=Standard", "URIDate": "2024-03-27" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_a&doctype=Standard", "URIDate": "2024-03-27" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_i&doctype=Standard", "URIDate": "2024-03-27" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2024-03-27" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2024-03-27" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2024-03-27" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106&doctype=Standard", "URIDate": "2024-03-27" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_117&doctype=Standard", "URIDate": "2024-03-27" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_16&doctype=Standard", "URIDate": "2024-03-27" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_35&doctype=Standard", "URIDate": "2024-03-27" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "51", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_51&doctype=Standard", "URIDate": "2024-03-27" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_c&doctype=Standard", "URIDate": "2024-03-27" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "54", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_d&doctype=Standard", "URIDate": "2024-03-27" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2024-03-27" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "54", "Subparagraph": "k", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_k&doctype=Standard", "URIDate": "2024-03-27" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard", "URIDate": "2024-03-27" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "61", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_61_a&doctype=Standard", "URIDate": "2024-03-27" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_61&doctype=Standard", "URIDate": "2024-03-27" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_66&doctype=Standard", "URIDate": "2024-03-27" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_69&doctype=Standard", "URIDate": "2024-03-27" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard", "URIDate": "2024-03-27" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "78", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_d&doctype=Standard", "URIDate": "2024-03-27" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2024-03-27" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2024-03-27" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2024-03-27" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2024-03-27" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79&doctype=Standard", "URIDate": "2024-03-27" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2024-03-27" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "81A", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_b&doctype=Standard", "URIDate": "2024-03-27" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_c&doctype=Standard", "URIDate": "2024-03-27" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_b&doctype=Standard", "URIDate": "2024-03-27" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_d&doctype=Standard", "URIDate": "2024-03-27" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_91_a&doctype=Standard", "URIDate": "2024-03-27" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_99&doctype=Standard", "URIDate": "2024-03-27" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2024-01-01", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2024-en-r&anchor=para_21&doctype=Standard", "URIDate": "2024-03-27" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_79&doctype=Standard", "URIDate": "2024-03-27" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2024-03-27" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2024-03-27" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2024-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI", "URIDate": "2024-03-27" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2024-03-27" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e_i&doctype=Standard", "URIDate": "2024-03-27" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2024-03-27" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "73", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73&doctype=Standard", "URIDate": "2024-03-27" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "75", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_75_b&doctype=Standard", "URIDate": "2024-03-27" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI", "URIDate": "2024-03-27" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2024-01-01", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS19_g2-7_TI", "URIDate": "2024-03-27" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2024-01-01", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2024-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2024-03-27" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2024-01-01", "Paragraph": "52", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2024-en-r&anchor=para_52_b&doctype=Standard", "URIDate": "2024-03-27" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2024-01-01", "Section": "Disclosures", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI", "URIDate": "2024-03-27" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2024-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2024-en-r&anchor=para_35_b_iv&doctype=Standard", "URIDate": "2024-03-27" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2024-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2024-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2024-03-27" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2024-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_66&doctype=Standard", "URIDate": "2024-03-27" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2024-01-01", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_67&doctype=Standard", "URIDate": "2024-03-27" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2024-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2024-03-27" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2024-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI", "URIDate": "2024-03-27" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2024-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_126&doctype=Standard", "URIDate": "2024-03-27" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2024-01-01", "Paragraph": "130", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_130_d_ii&doctype=Standard", "URIDate": "2024-03-27" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2024-01-01", "Paragraph": "134", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_134_a&doctype=Standard", "URIDate": "2024-03-27" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2024-01-01", "Paragraph": "134", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_134&doctype=Standard", "URIDate": "2024-03-27" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2024-01-01", "Paragraph": "135", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_135_a&doctype=Standard", "URIDate": "2024-03-27" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2024-01-01", "Paragraph": "135", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_135&doctype=Standard", "URIDate": "2024-03-27" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2024-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS37_g84-92_TI", "URIDate": "2024-03-27" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2024-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2024-03-27" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2024-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e_i&doctype=Standard", "URIDate": "2024-03-27" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2024-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e_ii&doctype=Standard", "URIDate": "2024-03-27" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2024-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e_iv&doctype=Standard", "URIDate": "2024-03-27" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2024-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e_vi&doctype=Standard", "URIDate": "2024-03-27" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2024-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2024-03-27" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2024-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118&doctype=Standard", "URIDate": "2024-03-27" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2024-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_126&doctype=Standard", "URIDate": "2024-03-27" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2024-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI", "URIDate": "2024-03-27" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2024-01-01", "Paragraph": "32A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_32A&doctype=Standard", "URIDate": "2024-03-27" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2024-01-01", "Paragraph": "76", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_76&doctype=Standard", "URIDate": "2024-03-27" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2024-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2024-03-27" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2024-01-01", "Paragraph": "79", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2024-03-27" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2024-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2024-en-r&anchor=para_50&doctype=Standard", "URIDate": "2024-03-27" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2024-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2024-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2024-03-27" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_10&doctype=Standard", "URIDate": "2024-03-27" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2024-03-27" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_21&doctype=Standard", "URIDate": "2024-03-27" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_25&doctype=Standard", "URIDate": "2024-03-27" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_28&doctype=Standard", "URIDate": "2024-03-27" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_31&doctype=Standard", "URIDate": "2024-03-27" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "44B", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44B_c&doctype=Standard", "URIDate": "2024-03-27" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "44B", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44B_d&doctype=Standard", "URIDate": "2024-03-27" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "44B", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44B_e&doctype=Standard", "URIDate": "2024-03-27" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "44H", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44H_b_iii&doctype=Standard", "URIDate": "2024-03-27" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard", "URIDate": "2024-03-27" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2024-03-27" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2024-03-27" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2024-03-27" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2024-03-27" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2024-03-27" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ix", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B13", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2024-03-27" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2024-03-27" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "93", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_d&doctype=Standard", "URIDate": "2024-03-27" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2024-03-27" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "93", "Subparagraph": "h", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_h_ii&doctype=Standard", "URIDate": "2024-03-27" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "93", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93&doctype=Standard", "URIDate": "2024-03-27" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "14", "IssueDate": "2024-01-01", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2024-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2024-03-27" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2024-01-01", "Paragraph": "120", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2024-03-27" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_33&doctype=Standard", "URIDate": "2024-03-27" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2024-03-27" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2024-03-27" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "53", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_b&doctype=Standard", "URIDate": "2024-03-27" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "53", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2024-03-27" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53&doctype=Standard", "URIDate": "2024-03-27" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "58", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_58&doctype=Standard", "URIDate": "2024-03-27" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_94&doctype=Standard", "URIDate": "2024-03-27" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_97&doctype=Standard", "URIDate": "2024-03-27" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2024-01-01", "Paragraph": "109", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_109&doctype=Standard", "URIDate": "2024-03-27" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2024-01-01", "Paragraph": "109A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2024-03-27" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2024-01-01", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_120&doctype=Standard", "URIDate": "2024-03-27" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2024-01-01", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_124&doctype=Standard", "URIDate": "2024-03-27" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2024-01-01", "Paragraph": "125", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_125&doctype=Standard", "URIDate": "2024-03-27" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2024-01-01", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_127&doctype=Standard", "URIDate": "2024-03-27" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2024-01-01", "Paragraph": "128", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_128_a_ii&doctype=Standard", "URIDate": "2024-03-27" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2024-01-01", "Paragraph": "128", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_128_a&doctype=Standard", "URIDate": "2024-03-27" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2024-01-01", "Paragraph": "132", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2024-03-27" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "44", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_44&doctype=Standard", "URIDate": "2024-03-27" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2024-03-27" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard", "URIDate": "2024-03-27" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2024-03-27" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_50&doctype=Standard", "URIDate": "2024-03-27" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "51", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_51_a&doctype=Standard", "URIDate": "2024-03-27" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2024-01-01", "Paragraph": "B67", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2024-01-01", "Paragraph": "33", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2024-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2024-03-27" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "20", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_a_i&doctype=Standard", "URIDate": "2024-03-27" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "21C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_21C&doctype=Standard", "URIDate": "2024-03-27" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "23B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2024-03-27" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_25&doctype=Standard", "URIDate": "2024-03-27" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_31&doctype=Standard", "URIDate": "2024-03-27" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_33&doctype=Standard", "URIDate": "2024-03-27" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_34&doctype=Standard", "URIDate": "2024-03-27" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2024-03-27" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "35I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2024-03-27" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "35K", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2024-03-27" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2024-03-27" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "39", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_39_a&doctype=Standard", "URIDate": "2024-03-27" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "39", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_39_b&doctype=Standard", "URIDate": "2024-03-27" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "42E", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2024-03-27" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "42I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_42I&doctype=Standard", "URIDate": "2024-03-27" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_6&doctype=Standard", "URIDate": "2024-03-27" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard", "URIDate": "2024-03-27" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "8", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_8_a&doctype=Standard", "URIDate": "2024-03-27" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "8", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_8_e&doctype=Standard", "URIDate": "2024-03-27" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "8", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_8_f&doctype=Standard", "URIDate": "2024-03-27" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "8", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_8_g&doctype=Standard", "URIDate": "2024-03-27" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "8", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_8&doctype=Standard", "URIDate": "2024-03-27" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Section": "Defined terms", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI", "URIDate": "2024-03-27" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI", "URIDate": "2024-03-27" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "23", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_c&doctype=Standard", "URIDate": "2024-03-27" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2024-03-27" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23&doctype=Standard", "URIDate": "2024-03-27" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2024-03-27" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2024-03-27" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2024-03-27" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "28", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2024-03-27" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_33&doctype=Standard", "URIDate": "2024-03-27" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI", "URIDate": "2024-03-27" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2024-01-01", "Paragraph": "7.2.34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2024-en-r&anchor=para_7.2.34&doctype=Standard", "URIDate": "2024-03-27" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2024-01-01", "Paragraph": "7.2.42", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2024-en-r&anchor=para_7.2.42&doctype=Standard", "URIDate": "2024-03-27" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2025-01-01", "Name": "IAS", "Number": "21", "IssueDate": "2024-01-01", "Paragraph": "A19", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2024-en-r&anchor=para_A19_f&doctype=Standard", "URIDate": "2024-03-27" }, "r172": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_102&doctype=Standard", "URIDate": "2024-03-27" }, "r173": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_103&doctype=Standard", "URIDate": "2024-03-27" }, "r174": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_108&doctype=Standard", "URIDate": "2024-03-27" }, "r175": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_70&doctype=Standard", "URIDate": "2024-03-27" }, "r176": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2024-03-27" }, "r177": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "82A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82A&doctype=Standard", "URIDate": "2024-03-27" }, "r178": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2024-03-27" }, "r179": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "37", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_37_c&doctype=Standard", "URIDate": "2024-03-27" }, "r180": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2024-01-01", "Paragraph": "138", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2024-03-27" }, "r181": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2024-01-01", "Paragraph": "147", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2024-03-27" }, "r182": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "32", "IssueDate": "2024-01-01", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2024-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2024-03-27" }, "r183": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "38", "IssueDate": "2024-01-01", "Paragraph": "119", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_119_c&doctype=Standard", "URIDate": "2024-03-27" }, "r184": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "38", "IssueDate": "2024-01-01", "Paragraph": "119", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_119_e&doctype=Standard", "URIDate": "2024-03-27" }, "r185": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "16", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2024-03-27" }, "r186": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2024-03-27" }, "r187": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "17", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_c&doctype=Standard", "URIDate": "2024-03-27" }, "r188": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2024-03-27" }, "r189": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "44C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44C&doctype=Standard", "URIDate": "2024-03-27" }, "r190": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "44D", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44D&doctype=Standard", "URIDate": "2024-03-27" }, "r191": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI", "URIDate": "2024-03-27" }, "r192": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Section": "C Reconciliation of liabilities arising from financing activities", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C_TI", "URIDate": "2024-03-27" }, "r193": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r194": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "93", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_d&doctype=Standard", "URIDate": "2024-03-27" }, "r195": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_94&doctype=Standard", "URIDate": "2024-03-27" }, "r196": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "B11", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_B11_a&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r197": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "B11", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_B11_b&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r198": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "B36", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_B36_a&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r199": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "B36", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_B36_b&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r200": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r201": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "IE60", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_IE60&doctype=Illustrative%20Examples", "URIDate": "2024-03-27" }, "r202": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2024-03-27" }, "r203": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2024-01-01", "Paragraph": "B89", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r204": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2024-01-01", "Paragraph": "B89", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_B89_d&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r205": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2024-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2024-03-27" }, "r206": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2024-01-01", "Paragraph": "96", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_96_a&doctype=Standard", "URIDate": "2024-03-27" }, "r207": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2024-01-01", "Paragraph": "96", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_96_b&doctype=Standard", "URIDate": "2024-03-27" }, "r208": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "35N", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2024-03-27" }, "r209": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_6&doctype=Standard", "URIDate": "2024-03-27" }, "r210": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "B11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r211": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "B11D", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B11D_a&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r212": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "B11D", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B11D&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r213": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "B35", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r214": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "B35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r215": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "IG31A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2024-03-27" }, "r216": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "IG40B", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_IG40B&doctype=Implementation%20Guidance", "URIDate": "2024-03-27" }, "r217": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23&doctype=Standard", "URIDate": "2024-03-27" }, "r218": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2024-03-27" }, "r219": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r220": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2024-03-27" }, "r221": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_104&doctype=Standard", "URIDate": "2024-03-27" }, "r222": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2024-03-27" }, "r223": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_108&doctype=Standard", "URIDate": "2024-03-27" }, "r224": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2024-03-27" }, "r225": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_a&doctype=Standard", "URIDate": "2024-03-27" }, "r226": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard", "URIDate": "2024-03-27" }, "r227": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2024-03-27" }, "r228": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2024-03-27" }, "r229": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78&doctype=Standard", "URIDate": "2024-03-27" }, "r230": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_85&doctype=Standard", "URIDate": "2024-03-27" }, "r231": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_37&doctype=Standard", "URIDate": "2024-03-27" }, "r232": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2024-03-27" }, "r233": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2024-03-27" }, "r234": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2024-01-01", "Paragraph": "135", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_135_b&doctype=Standard", "URIDate": "2024-03-27" }, "r235": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "20", "IssueDate": "2024-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2024-en-r&anchor=para_28&doctype=Standard", "URIDate": "2024-03-27" }, "r236": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "20", "IssueDate": "2024-01-01", "Paragraph": "39", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2024-en-r&anchor=para_39_b&doctype=Standard", "URIDate": "2024-03-27" }, "r237": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2024-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2024-03-27" }, "r238": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2024-01-01", "Paragraph": "119", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_119&doctype=Standard", "URIDate": "2024-03-27" }, "r239": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "40", "IssueDate": "2024-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2024-03-27" }, "r240": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "41", "IssueDate": "2024-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2024-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2024-03-27" }, "r241": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17&doctype=Standard", "URIDate": "2024-03-27" }, "r242": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2024-03-27" }, "r243": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2024-03-27" }, "r244": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard", "URIDate": "2024-03-27" }, "r245": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard", "URIDate": "2024-03-27" }, "r246": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "93", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_d&doctype=Standard", "URIDate": "2024-03-27" }, "r247": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "93", "Subparagraph": "h", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_h_ii&doctype=Standard", "URIDate": "2024-03-27" }, "r248": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "93", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_h&doctype=Standard", "URIDate": "2024-03-27" }, "r249": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard", "URIDate": "2024-03-27" }, "r250": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard", "URIDate": "2024-03-27" } } }